<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AZITHROMYCIN- azithromycin monohydrateÂ powder, for suspensionÂ </strong><br>Preferred Pharmaceuticals, Inc.<br></p></div>
<h1><span class="Bold">AZITHROMYCIN FOR ORAL SUSPENSION USP</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1194b241-deb2-4592-8151-2e38dbd47fe7"></a><a name="section-1"></a><p></p>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin for oral suspension should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_926b7496-ce8f-4feb-9392-0df39df20201"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Azithromycin for oral suspension USP contains the active ingredient azithromycin, USP, an azalide, a subclass of macrolide antibiotics, for oral administration. Azithromycin, USP has the chemical name <span class="Italics">(2R,3S,4R,5R,8R, 10R,11R,12S,13S,14R)</span>-13-[(2,6-dideoxy-3-<span class="Italics">C</span>-methyl-3-<span class="Italics">O</span>-methyl-Î±-<span class="Italics">L-ribo-</span>hexopyranosyl) oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3- (dimethylamino)-Î²-<span class="Italics">D-xylo</span>-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Azithromycin, USP is derived from erythromycin; however, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring.</p>
<p>Azithromycin, USP has the following structural formula:</p>
<div class="Figure">
<a name="id306"></a><img alt="Chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=035ce971-cf46-40c0-9b2f-ae52ab4e3468&amp;name=image-01.jpg">
</div>
<p> C<span class="Sub">38</span>H<span class="Sub">72</span>N<span class="Sub">2</span>O<span class="Sub">12</span> M.W. 749.0</p>
<p>Azithromycin, USP, as the monohydrate, is a white crystalline powder with a molecular formula of C<span class="Sub">38</span>H<span class="Sub">72</span>N<span class="Sub">2</span>O<span class="Sub">12</span>â€¢H<span class="Sub">2</span>O and a molecular weight of 767.0.</p>
<p>Azithromycin for oral suspension USP is supplied in bottles containing azithromycin monohydrate powder equivalent to 300 mg, 600 mg, 900 mg or 1200 mg azithromycin, USP per bottle and the following inactive ingredients: ammonio methacrylate copolymer, banana flavor, cherry flavor, colloidal silicon dioxide, FD&amp;C Red No. 40, hydroxypropyl cellulose, sucrose, tribasic sodium phosphate anhydrous, vanilla flavor, and xanthan gum. After constitution, each 5 mL of suspension contains 100 mg or 200 mg of azithromycin, USP.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_e07c9209-7877-418f-b1ce-8f7c3df4ece4"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5ab8f45e-e042-45a5-9d07-722bd9bc131a"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Following oral administration of a single 500 mg dose (two 250 mg tablets) to 36 fasted healthy male volunteers, the mean (SD) pharmacokinetic parameters were AUC<span class="Sub">0-72</span> = 4.3 (1.2) mcgÂ·h/mL; C<span class="Sub">max</span> = 0.5 (0.2) mcg/mL; T<span class="Sub">max </span>= 2.2 (0.9) hours. </p>
<p>With a regimen of 500 mg (two 250 mg capsules*) on day 1, followed by 250 mg daily (one 250 mg capsule) on days 2 through 5, the pharmacokinetic parameters of azithromycin in plasma in healthy young adults (18 to 40 years of age) are portrayed in the chart below. C<span class="Sub">min</span> and C<span class="Sub">max</span> remained essentially unchanged from day 2 through day 5 of therapy.</p>
<table width="100%">
<col width="36%">
<col width="14%">
<col width="8%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="3" valign="top">*Azithromycin 250 mg tablets are bioequivalent to 250 mg capsules in the fasted state. Azithromycin 250 mg capsules are no longer commercially available.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Pharmacokinetic Parameters (Mean)</p></td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First">Total n = 12</p>
<p><span class="Underline">Day 1</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First">Â </p>
<p><span class="Underline">Day 5</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">C<span class="Sub">max</span> (mcg/mL)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.41</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.24</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">T<span class="Sub">max </span>(h)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">AUC<span class="Sub">0-24</span> (mcgÂ·h/mL)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">C<span class="Sub">min</span> (mcg/mL)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.05</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.05</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Urinary Excret. (% dose)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6.5</p></td>
</tr>
</tbody>
</table>
<p>In a two-way crossover study, 12 adult healthy volunteers (6 males, 6 females) received 1,500 mg of azithromycin administered in single daily doses over either 5 days (two 250 mg tablets on day 1, followed by one 250 mg tablet on days 2 to 5) or 3 days (500 mg per day for days 1 to 3). Due to limited serum samples on day 2 (3 day regimen) and days 2 to 4 (5 day regimen), the serum concentration-time profile of each subject was fit to a 3 compartment model and the AUC<span class="Sub">0-âˆž</span> for the fitted concentration profile was comparable between the 5 day and 3 day regimens.</p>
<table width="100%">
<col width="29%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="12%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Total AUC for the entire 3 day and 5 day regimens</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"><p class="First">3 Day Regimen</p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"><p class="First">5 Day Regimen</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">
<p class="First">Pharmacokinetic Parameter</p>
<p>[mean (SD)]</p>
</td>
<td class="Botrule Rrule"><p class="First">Day 1</p></td>
<td class="Botrule Rrule"><p class="First">Day 3</p></td>
<td class="Botrule Rrule"><p class="First">Day 1</p></td>
<td class="Botrule Rrule"><p class="First">Day 5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">C<span class="Sub">max </span>(serum, mcg/mL)</p></td>
<td class="Botrule Rrule"><p class="First">0.44 (0.22)</p></td>
<td class="Botrule Rrule"><p class="First">0.54 (0.25)</p></td>
<td class="Botrule Rrule"><p class="First">0.43 (0.20)</p></td>
<td class="Botrule Rrule"><p class="First">0.24 (0.06)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Serum AUC<span class="Sub">0-âˆž</span> (mcgÂ·hr/mL)</p></td>
<td class="Botrule Rrule" align="center" colspan="2"><p class="First">17.4 (6.2)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center" colspan="2"><p class="First">14.9 (3.1)<a href="#footnote-1" class="Sup">*</a></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Serum T<span class="Sub">1/2</span></p></td>
<td class="Botrule Rrule" align="center" colspan="2"><p class="First">71.8 hr</p></td>
<td class="Botrule Rrule" align="center" colspan="2"><p class="First">68.9 hr</p></td>
</tr>
</tbody>
</table>
<p>Median azithromycin exposure (AUC<span class="Sub">0-288</span>) in mononuclear (MN) and polymorphonuclear (PMN) leukocytes following either the 5 day or 3 day regimen was more than a 1000 fold and 800 fold greater than in serum, respectively. Administration of the same total dose with either the 5 day or 3 day regimen may be expected to provide comparable concentrations of azithromycin within MN and PMN leukocytes. </p>
<p>Two azithromycin 250 mg tablets are bioequivalent to a single 500 mg tablet.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a221225-347c-47a1-9c7c-8fc461ffa99c"></a><a name="section-3.2"></a><p></p>
<h2>Absorption</h2>
<p class="First">The absolute bioavailability of azithromycin 250 mg capsules is 38%. </p>
<p>In a two-way crossover study in which 12 healthy subjects received a single 500 mg dose of azithromycin (two 250 mg tablets) with or without a high fat meal, food was shown to increase C<span class="Sub">max</span> by 23% but had no effect on AUC.</p>
<p>When azithromycin suspension was administered with food to 28 adult healthy male subjects, C<span class="Sub">max</span> increased by 56% and AUC was unchanged.</p>
<p>The AUC of azithromycin was unaffected by coadministration of an antacid containing aluminum and magnesium hydroxide with azithromycin capsules; however, the C<span class="Sub">max </span>was reduced by 24%. Administration of cimetidine (800 mg) two hours prior to azithromycin had no effect on azithromycin absorption.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0d015e3d-002e-450d-973c-96a84a573a9e"></a><a name="section-3.3"></a><p></p>
<h2>Distribution</h2>
<p class="First">The serum protein binding of azithromycin is variable in the concentration range approximating human exposure, decreasing from 51% at 0.02 mcg/mL to 7% at 2 mcg/mL. </p>
<p>Following oral administration, azithromycin is widely distributed throughout the body with an apparent steady-state volume of distribution of 31.1 L/kg. Greater azithromycin concentrations in tissues than in plasma or serum were observed. High tissue concentrations should not be interpreted to be quantitatively related to clinical efficacy. The antimicrobial activity of azithromycin is pH related and appears to be reduced with decreasing pH. However, the extensive distribution of drug to tissues may be relevant to clinical activity.</p>
<p>Selected tissue (or fluid) concentration and tissue (or fluid) to plasma/serum concentration ratios are shown in the following table:</p>
<a name="_Refid_0675c878-426a-4020-a098-ab480e9d9"></a><table width="100%">
<caption><span>AZITHROMYCIN CONCENTRATIONS FOLLOWING A 500 mg DOSE (TWO 250 mg CAPSULES) IN ADULTS<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>Â </span></caption>
<col width="15%">
<col width="12%">
<col width="29%">
<col width="29%">
<col width="15%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Azithromycin tissue concentrations were originally determined using 250 mg capsules.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€ </a></dt>
<dd>Sample was obtained 2 to 4 hours after the first dose.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">â€¡</a></dt>
<dd>Sample was obtained 10 to 12 hours after the first dose.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">Â§</a></dt>
<dd>Dosing regimen of two doses of 250 mg each, separated by 12 hours.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">Â¶</a></dt>
<dd>Sample was obtained 19 hours after a single 500 mg dose.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">TISSUE OR FLUID</p></td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First">TIME AFTER</p>
<p>DOSE (h)</p>
</td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First">TISSUE OR FLUID CONCENTRATION</p>
<p>(mcg/g or mcg/mL)</p>
</td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First">CORRESPONDING PLASMA OR SERUM</p>
<p>LEVEL (mcg/mL)</p>
</td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First"><span class="Underline">TISSUE (FLUID)</span></p>
<p>PLASMA (SERUM)</p>
<p>RATIO</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">SKIN</p></td>
<td class="Botrule Rrule" align="center"><p class="First">72 to 96</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.012</p></td>
<td class="Botrule Rrule" align="center"><p class="First">35</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">LUNG</p></td>
<td class="Botrule Rrule" align="center"><p class="First">72 to 96</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.012</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&gt; 100</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">SPUTUM</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">â€ </a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 to 4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.64</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">SPUTUM</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">â€¡</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">10 to 12</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.1</p></td>
<td class="Botrule Rrule" align="center"><p class="First">30</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">TONSIL<a name="footnote-reference-5" href="#footnote-5" class="Sup">Â§</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">9 to 18</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.03</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&gt; 100</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">TONSIL<a href="#footnote-5" class="Sup">Â§</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">180</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.006</p></td>
<td class="Botrule Rrule" align="center"><p class="First">&gt; 100</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">CERVIX<a name="footnote-reference-6" href="#footnote-6" class="Sup">Â¶</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">19</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.04</p></td>
<td class="Botrule Rrule" align="center"><p class="First">70</p></td>
</tr>
</tbody>
</table>
<p>The extensive tissue distribution was confirmed by examination of additional tissues and fluids (bone, ejaculum, prostate, ovary, uterus, salpinx, stomach, liver, and gallbladder). As there are no data from adequate and well-controlled studies of azithromycin treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in these additional body sites, the clinical importance of these tissue concentration data is unknown.</p>
<p>Following a regimen of 500 mg on the first day and 250 mg daily for 4 days, only very low concentrations were noted in cerebrospinal fluid (less than 0.01 mcg/mL) in the presence of non-inflamed meninges.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8b35e656-ce56-4910-833f-4a94cc2441df"></a><a name="section-3.4"></a><p></p>
<h2>Metabolism</h2>
<p class="First"><span class="Italics">In vitro </span>and <span class="Italics">in vivo </span>studies to assess the metabolism of azithromycin have not been performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_93ffe8ff-c748-4bba-8356-830fa09c3f7b"></a><a name="section-3.5"></a><p></p>
<h2>Elimination</h2>
<p class="First">Plasma concentrations of azithromycin following single 500 mg oral and i.v. doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours. The prolonged terminal half-life is thought to be due to extensive uptake and subsequent release of drug from tissues.</p>
<p>Biliary excretion of azithromycin, predominantly as unchanged drug, is a major route of elimination. Over the course of a week, approximately 6% of the administered dose appears as unchanged drug in urine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a5f62d0f-9973-4144-af1c-f882a4d92fa0"></a><a name="section-3.6"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_83080b33-9c49-4aeb-b0c8-14465551e261"></a><a name="section-3.6.1"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span></h3>
<p class="First">Azithromycin pharmacokinetics were investigated in 42 adults (21 to 85 years of age) with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Following the oral administration of a single 1,000 mg dose of azithromycin, mean C<span class="Sub">max</span> and AUC<span class="Sub">0-120</span> increased by 5.1% and 4.2%, respectively in subjects with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR 10 to 80 mL/min) compared to subjects with normal renal function (GFR &gt; 80 mL/min). The mean C<span class="Sub">max</span> and AUC<span class="Sub">0-120</span> increased 61% and 35%, respectively in subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR &lt; 10 mL/min) compared to subjects with normal renal function (GFR &gt;80 mL/min) (see <span class="Bold"><a href="#i4i_dosage_admin_id_5f9a39bc-e310-40e9-87ca-c4002c87c14d">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_366c54af-3d22-4162-a18c-01b5d82f2bcb"></a><a name="section-3.6.2"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></h3>
<p class="First">The pharmacokinetics of azithromycin in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0b9f873d-b6ad-4cc6-bf12-64afef8441e3"></a><a name="section-3.6.3"></a><p></p>
<h3><span class="Bold">Gender</span></h3>
<p class="First">There are no significant differences in the disposition of azithromycin between male and female subjects. No dosage adjustment is recommended based on gender.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_455af7ec-b897-4c50-9f0e-3f7552e6e76c"></a><a name="section-3.6.4"></a><p></p>
<h3><span class="Bold">Geriatric Patients</span></h3>
<p class="First">When studied in healthy elderly subjects aged 65 to 85 years, the pharmacokinetic parameters of azithromycin in elderly men were similar to those in young adults; however, in elderly women, although higher peak concentrations (increased by 30 to 50%) were observed, no significant accumulation occurred.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0fed9ae5-ad3f-41b0-b683-223dc3acc0c9"></a><a name="section-3.6.5"></a><p></p>
<h3><span class="Bold">Pediatric Patients</span></h3>
<p class="First">In two clinical studies, azithromycin for oral suspension was dosed at 10 mg/kg on day 1, followed by 5 mg/kg on days 2 through 5 to two groups of pediatric patients (aged 1 to 5 years and 5 to 15 years, respectively). The mean pharmacokinetic parameters on day 5 were C<span class="Sub">max </span>= 0.216 mcg/mL, T<span class="Sub">max</span> = 1.9 hours, and AUC<span class="Sub">0-24 </span>= 1.822 mcgÂ·hr/mL for the 1 to 5 year old group and were C<span class="Sub">max</span> = 0.383 mcg/mL, T<span class="Sub">max</span> = 2.4 hours, and AUC<span class="Sub">0-24 </span>= 3.109 mcgÂ·hr/mL for the 5 to 15 year old group.</p>
<p>Two clinical studies were conducted in 68 pediatric patients aged 3 to 16 years to determine the pharmacokinetics and safety of azithromycin for oral suspension. Azithromycin was administered following a low-fat breakfast.</p>
<p>The first study consisted of 35 pediatric patients treated with 20 mg/kg/day (maximum daily dose 500 mg) for 3 days of whom 34 patients were evaluated for pharmacokinetics.</p>
<p>In the second study, 33 pediatric patients received doses of 12 mg/kg/day (maximum daily dose 500 mg) for 5 days of whom 31 patients were evaluated for pharmacokinetics.</p>
<p>In both studies, azithromycin concentrations were determined over a 24 hour period following the last daily dose. Patients weighing above 25 kg in the 3 day study or 41.7 kg in the 5 day study received the maximum adult daily dose of 500 mg. Eleven patients (weighing 25 kg or less) in the first study and 17 patients (weighing 41.7 kg or less) in the second study received a total dose of 60 mg/kg. The following table shows pharmacokinetic data in the subset of pediatric patients who received a total dose of 60 mg/kg.</p>
<table width="100%">
<col width="28%">
<col width="21%">
<col width="21%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">
<p class="First">Pharmacokinetic Parameter</p>
<p>[mean (SD)]</p>
</td>
<td class="Botrule Rrule Toprule">
<p class="First">3 Day Regimen</p>
<p>(20 mg/kg x 3 days)</p>
</td>
<td class="Botrule Rrule Toprule">
<p class="First">5 Day Regimen</p>
<p>(12 mg/kg x 5 days)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">n</p></td>
<td class="Botrule Rrule"><p class="First">11</p></td>
<td class="Botrule Rrule"><p class="First">17</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">C<span class="Sub">max </span>(mcg/mL)</p></td>
<td class="Botrule Rrule"><p class="First">1.1 (0.4)</p></td>
<td class="Botrule Rrule"><p class="First">0.5 (0.4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">T<span class="Sub">max</span> (hr)</p></td>
<td class="Botrule Rrule"><p class="First">2.7 (1.9)</p></td>
<td class="Botrule Rrule"><p class="First">2.2 (0.8)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">AUC<span class="Sub">0-24 </span>(mcgÂ·hr/mL)</p></td>
<td class="Botrule Rrule"><p class="First">7.9 (2.9)</p></td>
<td class="Botrule Rrule"><p class="First">3.9 (1.9)</p></td>
</tr>
</tbody>
</table>
<p>The similarity of the overall exposure (AUC<span class="Sub">0-âˆž</span>) between the 3 day and 5 day regimens in pediatric patients is unknown.</p>
<p>Single dose pharmacokinetics in pediatric patients given doses of 30 mg/kg have not been studied (see <span class="Bold"><a href="#i4i_dosage_admin_id_5f9a39bc-e310-40e9-87ca-c4002c87c14d">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b8a30bfd-6927-4543-b281-58f1a0a6af20"></a><a name="section-3.7"></a><p></p>
<h2>Drug-Drug Interactions</h2>
<p class="First">Drug interaction studies were performed with azithromycin and other drugs likely to be coadministered. The effects of coadministration of azithromycin on the pharmacokinetics of other drugs are shown in <span class="Bold">Table 1</span> and the effect of other drugs on the pharmacokinetics of azithromycin are shown in <span class="Bold">Table 2</span>.</p>
<p>Coadministration of azithromycin at therapeutic doses had a modest effect on the pharmacokinetics of the drugs listed in <span class="Bold">Table 1</span>. No dosage adjustment of drugs listed in <span class="Bold">Table 1</span> is recommended when coadministered with azithromycin.</p>
<p>Coadministration of azithromycin with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin. Nelfinavir significantly increased the C<span class="Sub">max </span>and AUC of azithromycin. No dosage adjustment of azithromycin is recommended when administered with drugs listed in <span class="Bold">Table 2</span> (see <span class="Bold">PRECAUTIONS, <a href="#i4i_interactions_id_4abb8a91-5a4d-4267-b492-1d6e24f96db1">Drug Interactions</a></span>).</p>
<a name="_Refid_37c519a4-e6bf-4a37-97db-cc93fc071"></a><table width="100%">
<caption><span>Table 1. Drug Interactions: Pharmacokinetic Parameters for Coadministered Drugs in the Presence of Azithromycin</span></caption>
<col width="21%">
<col width="22%">
<col width="22%">
<col width="5%">
<col width="17%">
<col width="13%">
<tfoot>
<tr class="First Last"><td class="Botrule" align="left" colspan="6" valign="top">NA - Not Available<br>Mean rifabutin concentrations one-half day after the last dose of rifabutin were 60 ng/mL when coadministered with azithromycin and 71 ng/mL when coadministered with placebo.</td></tr>
<tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>- 90% Confidence interval not reported</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">
<p class="First">Coadministered</p>
<p>Drug</p>
</td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2">
<p class="First">Dose of</p>
<p>Coadministered Drug</p>
</td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2"><p class="First">Dose of Azithromycin</p></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2"><p class="First">n</p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2">
<p class="First">Ratio (with/without azithromycin) of Coadministered Drug Pharmacokinetic Parameters</p>
<p>(90% CI); No Effect = 1</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Mean C<span class="Sub">max</span></p></td>
<td class="Botrule Rrule"><p class="First">Mean AUC</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Atorvastatin</p></td>
<td class="Botrule Rrule"><p class="First">10 mg/day x 8 days</p></td>
<td class="Botrule Rrule"><p class="First">500 mg/day PO on days 6 to 8</p></td>
<td class="Botrule Rrule"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">0.83</p>
<p>(0.63 to 1.08)</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">1.01</p>
<p>(0.81 to 1.25)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Carbamazepine</p></td>
<td class="Botrule Rrule"><p class="First">200 mg/day x 2 days, then 200 mg BID x 18 days</p></td>
<td class="Botrule Rrule"><p class="First">500 mg/day PO for days 16 to 18</p></td>
<td class="Botrule Rrule"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">0.97</p>
<p>(0.88 to 1.06)</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">0.96</p>
<p>(0.88 to 1.06)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Cetirizine</p></td>
<td class="Botrule Rrule"><p class="First">20 mg/day x 11 days</p></td>
<td class="Botrule Rrule"><p class="First">500 mg PO on day 7, then 250 mg/day on days 8 to 11</p></td>
<td class="Botrule Rrule"><p class="First">14</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">1.03</p>
<p>(0.93 to 1.14)</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">1.02</p>
<p>(0.92 to 1.13)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Didanosine</p></td>
<td class="Botrule Rrule"><p class="First">200 mg PO BID x 21 days</p></td>
<td class="Botrule Rrule"><p class="First">1,200 mg/day PO on days 8 to 21</p></td>
<td class="Botrule Rrule"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">1.44</p>
<p>(0.85 to 2.43)</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">1.14 </p>
<p>(0.83 to 1.57)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Efavirenz</p></td>
<td class="Botrule Rrule"><p class="First">400 mg/day x 7 days</p></td>
<td class="Botrule Rrule"><p class="First">600 mg PO on day 7</p></td>
<td class="Botrule Rrule"><p class="First">14</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.04<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.95<a href="#footnote-7" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Fluconazole</p></td>
<td class="Botrule Rrule"><p class="First">200 mg PO single dose</p></td>
<td class="Botrule Rrule"><p class="First">1,200 mg PO single dose</p></td>
<td class="Botrule Rrule"><p class="First">18</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">1.04</p>
<p>(0.98 to 1.11)</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">1.01</p>
<p>(0.97 to 1.05)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Indinavir</p></td>
<td class="Botrule Rrule"><p class="First">800 mg TID x 5 days</p></td>
<td class="Botrule Rrule"><p class="First">1,200 mg PO on day 5</p></td>
<td class="Botrule Rrule"><p class="First">18</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">0.96</p>
<p>(0.86 to 1.08)</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">0.9</p>
<p>(0.81 to 1)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Midazolam</p></td>
<td class="Botrule Rrule"><p class="First">15 mg PO on day 3</p></td>
<td class="Botrule Rrule"><p class="First">500 mg/day PO x 3 days</p></td>
<td class="Botrule Rrule"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">1.27</p>
<p>(0.89 to 1.81)</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">1.26</p>
<p>(1.01 to 1.56)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Nelfinavir</p></td>
<td class="Botrule Rrule"><p class="First">750 mg TID x 11 days</p></td>
<td class="Botrule Rrule"><p class="First">1,200 mg PO on day 9</p></td>
<td class="Botrule Rrule"><p class="First">14</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">0.90</p>
<p>(0.81 to 1.01)</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">0.85 </p>
<p>(0.78 to 0.93)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Rifabutin</p></td>
<td class="Botrule Rrule"><p class="First">300 mg/day x 10 days</p></td>
<td class="Botrule Rrule"><p class="First">500 mg PO on day 1, then 250 mg/day on days 2 to 10</p></td>
<td class="Botrule Rrule"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">See footnote below</p></td>
<td class="Botrule Rrule" align="center"><p class="First">NA</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Sildenafil</p></td>
<td class="Botrule Rrule"><p class="First">100 mg on days 1 and 4</p></td>
<td class="Botrule Rrule"><p class="First">500 mg/day PO x 3 days</p></td>
<td class="Botrule Rrule"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">1.16</p>
<p>(0.86 to 1.57)</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">0.92</p>
<p>(0.75 to 1.12)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Theophylline</p></td>
<td class="Botrule Rrule"><p class="First">4 mg/kg I.V. on days 1, 11, 25</p></td>
<td class="Botrule Rrule"><p class="First">500 mg PO on day 7, then 250 mg/day on days 8 to 11</p></td>
<td class="Botrule Rrule"><p class="First">10</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">1.19</p>
<p>(1.02 to 1.40)</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">1.02</p>
<p>(0.86 to 1.22)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Theophylline</p></td>
<td class="Botrule Rrule"><p class="First">300 mg PO BID x 15 days</p></td>
<td class="Botrule Rrule"><p class="First">500 mg PO on day 6, then 250 mg/day on days 7 to 10</p></td>
<td class="Botrule Rrule"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">1.09</p>
<p>(0.92 to 1.29)</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">1.08</p>
<p>(0.89 to 1.31)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Triazolam</p></td>
<td class="Botrule Rrule"><p class="First">0.125 mg on day 2</p></td>
<td class="Botrule Rrule">
<p class="First">500 mg PO on day1, then 250 mg/day</p>
<p>on day 2</p>
</td>
<td class="Botrule Rrule"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.06<a href="#footnote-7" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.02<a href="#footnote-7" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Trimethoprim/ Sulfamethoxazole</p></td>
<td class="Botrule Rrule"><p class="First">160 mg/800 mg/day PO x 7 days</p></td>
<td class="Botrule Rrule"><p class="First">1,200 mg PO on day 7</p></td>
<td class="Botrule Rrule"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">0.85</p>
<p>(0.75 to 0.97)</p>
<p>/0.90</p>
<p>(0.78 to 1.03)</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">0.87</p>
<p>(0.80 to 0.95)</p>
<p>/0.96</p>
<p>(0.88 to 1.03)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Zidovudine</p></td>
<td class="Botrule Rrule"><p class="First">500 mg/day PO x 21 days</p></td>
<td class="Botrule Rrule"><p class="First">600 mg/day PO x 14 days</p></td>
<td class="Botrule Rrule"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">1.12</p>
<p>(0.42 to 3.02)</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">0.94</p>
<p>(0.52 to 1.70)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Zidovudine</p></td>
<td class="Botrule Rrule"><p class="First">500 mg/day PO x 21 days</p></td>
<td class="Botrule Rrule"><p class="First">1,200 mg/day PO x 14 days</p></td>
<td class="Botrule Rrule"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">1.31</p>
<p>(0.43 to 3.97)</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">1.30</p>
<p>(0.69 to 2.43)</p>
</td>
</tr>
</tbody>
</table>
<a name="_Refid_49d9b1c6-134e-47f6-a43c-b7f2c91a2"></a><table width="100%">
<caption><span>Table 2. Drug Interactions: Pharmacokinetic Parameters for Azithromycin in the Presence of Coadministered Drugs (see PRECAUTIONS, <a href="#i4i_interactions_id_4abb8a91-5a4d-4267-b492-1d6e24f96db1">Drug Interactions</a>)</span></caption>
<col width="18%">
<col width="21%">
<col width="27%">
<col width="5%">
<col width="17%">
<col width="12%">
<tfoot>
<tr class="First Last"><td class="Botrule" align="left" colspan="12" valign="top">NA - Not available</td></tr>
<tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>- 90% Confidence interval not reported</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2"><p class="First">Coadministered Drug</p></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2"><p class="First">Dose of Coadministered Drug</p></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2"><p class="First">Dose of Azithromycin</p></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2"><p class="First">n</p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2">
<p class="First">Ratio (with/without</p>
<p>coadministered drug) of Azithromycin Pharmacokinetic</p>
<p>Parameters (90% CI);</p>
<p>No Effect = 1</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Mean C<span class="Sub">max</span></p></td>
<td class="Botrule Rrule"><p class="First">Mean AUC</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Efavirenz</p></td>
<td class="Botrule Rrule"><p class="First">400 mg/day x 7 days</p></td>
<td class="Botrule Rrule"><p class="First">600 mg PO on day 7</p></td>
<td class="Botrule Rrule"><p class="First">14</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">1.22</p>
<p>(1.04 to 1.42)</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">0.92<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Fluconazole</p></td>
<td class="Botrule Rrule"><p class="First">200 mg PO single dose</p></td>
<td class="Botrule Rrule"><p class="First">1,200 mg PO single dose</p></td>
<td class="Botrule Rrule"><p class="First">18</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">0.82</p>
<p>(0.66 to 1.02)</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">1.07</p>
<p>(0.94 to 1.22)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Nelfinavir</p></td>
<td class="Botrule Rrule"><p class="First">750 mg TID x 11 days</p></td>
<td class="Botrule Rrule"><p class="First">1,200 mg PO on day 9</p></td>
<td class="Botrule Rrule"><p class="First">14</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">2.36</p>
<p>(1.77 to 3.15)</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">2.12</p>
<p>(1.80 to 2.50)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Rifabutin</p></td>
<td class="Botrule Rrule"><p class="First">300 mg/day x 10 days</p></td>
<td class="Botrule Rrule"><p class="First">500 mg PO on day 1, then 250 mg/day on days 2 to 10</p></td>
<td class="Botrule Rrule"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">See footnote below</p></td>
<td class="Botrule Rrule" align="center"><p class="First">NA</p></td>
</tr>
</tbody>
</table>
<p>Mean azithromycin concentrations one day after the last dose were 53 ng/mL when coadministered with 300 mg daily rifabutin and 49 ng/mL when coadministered with placebo.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_38cd05e2-693e-4aeb-a49a-ad97d90b6171"></a><a name="section-3.8"></a><p></p>
<h2>Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d51b6519-7acd-450c-afbe-4ac9436ebb81"></a><a name="section-3.8.1"></a><p></p>
<h3><span class="Bold">Cardiac Electrophysiology</span></h3>
<p class="First">QTc interval prolongation was studied in a randomized, placebo-controlled parallel trial in 116 healthy subjects who received either chloroquine (1000 mg) alone or in combination with azithromycin (500 mg, 1000 mg, and 1500 mg once daily). Coadministration of azithromycin increased the QTc interval in a dose-and concentration-dependent manner. In comparison to chloroquine alone, the maximum mean (95% upper confidence bound) increases in QTcF were 5 </p>
<p>(10) ms, 7 (12) ms and 9 (14) ms with the coadministration of 500 mg, 1000 mg and 1500 mg azithromycin, respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_41c20d55-2bde-4e2b-ba8a-efa2f4808a55"></a><a name="section-3.9"></a><p></p>
<h2>Microbiology </h2>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_14396aae-e66c-4c0a-9b9d-469f6327d1ba"></a><a name="section-3.9.1"></a><p></p>
<h3><span class="Bold">Mechanism of Action</span></h3>
<p class="First">Azithromycin binds to the 23S rRNA of the bacterial 50S ribosomal subunit. It blocks protein synthesis by inhibiting the transpeptidation/translocation step of protein synthesis and by inhibiting the assembly of the 50S ribosomal subunit. </p>
<p>Azithromycin concentrates in phagocytes and fibroblasts as demonstrated by <span class="Italics">in vitro</span> incubation techniques. The ratio of intracellular to extracellular concentration was &gt; 30 after one hour incubation. <span class="Italics">In vivo</span> studies suggest that concentration in phagocytes may contribute to drug distribution to inflamed tissues. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b4449597-95c9-4c04-995f-b4083d02fddb"></a><a name="section-3.9.2"></a><p></p>
<h3><span class="Bold">Mechanism of Resistance </span></h3>
<p class="First">The most frequently encountered mechanism of resistance to azithromycin is modification of the 23S rRNA at positions corresponding to A2058 and A2059 in the <span class="Italics">Escherichia coli</span> numbering system. In addition to cross resistance with other macrolides (erythromycin and clarithromycin), ribosomal modification may determine resistance to other antibiotic classes (lincosamides and streptogramins B) that bind to overlapping ribosomal sites.</p>
<p>Azithromycin has been shown to be active against most isolates of the following bacteria, both <span class="Italics">in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (see <span class="Bold"><a href="#i4i_indications_id_b7d8c67f-6ac6-49d6-ac4f-d30514926001">INDICATIONS AND USAGE</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_29a3225a-3aea-492d-960b-3933714edcbd"></a><a name="section-3.9.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Gram-positive bacteria</span></span></h3>
<p class="First"><span class="Italics"> Staphylococcus aureus</span></p>
<p><span class="Italics"> Streptococcus agalactiae</span></p>
<p><span class="Italics"> Streptococcus pneumoniae</span></p>
<p><span class="Italics"> Streptococcus pyogenes</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_da39fbfd-d097-4685-89f3-d7cde9b7160d"></a><a name="section-3.9.4"></a><p></p>
<h3><span class="Bold"><span class="Italics">Gram-negative bacteria</span></span></h3>
<p class="First"><span class="Italics"> Haemophilus ducreyi</span></p>
<p><span class="Italics"> Haemophilus influenzae</span></p>
<p><span class="Italics"> Moraxella catarrhalis</span></p>
<p><span class="Italics"> Neisseria gonorrhoeae</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8341bbfc-dc64-4315-ac70-816f00bb7877"></a><a name="section-3.9.5"></a><p></p>
<h3><span class="Bold"><span class="Italics">â€œOtherâ€? bacteria</span></span></h3>
<p class="First"><span class="Italics"> Chlamydophila pneumoniae</span></p>
<p><span class="Italics"> Chlamydia trachomatis</span></p>
<p><span class="Italics"> Mycoplasma pneumoniae</span></p>
<p>The following <span class="Italics">in vitro </span>data are available, <span class="Bold"><span class="Underline">but their clinical significance is unknown</span>.</span></p>
<p>At least 90% of the following bacteria exhibit an <span class="Italics">in vitro </span><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) less than or equal to the azithromycin susceptible breakpoint of â‰¤ 4 mcg/mL. However, safety and effectiveness of azithromycin in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these bacteria have not been established in adequate and well-controlled trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b1290c29-8775-4857-add9-0f21865e4f5c"></a><a name="section-3.9.6"></a><p></p>
<h3><span class="Bold"><span class="Italics">Gram-positive bacteria</span></span></h3>
<p class="First"> Beta-hemolytic streptococci (Groups C, F, G)</p>
<p> Viridans group streptococci</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e81890db-5ba9-4304-a7fc-2b1f6066c68a"></a><a name="section-3.9.7"></a><p></p>
<h3><span class="Bold"><span class="Italics">Gram-negative bacteria</span></span></h3>
<p class="First"><span class="Italics"> Bordetella <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6d6cd81a-8a5c-4b54-9790-df3f38a16d5c"></a><a name="section-3.9.8"></a><p></p>
<h3><span class="Bold"><span class="Italics">Anaerobic bacteria</span></span></h3>
<p class="First"><span class="Italics"> Peptostreptococcus </span>species</p>
<p><span class="Italics"> Prevotella bivia</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aef84f0a-658c-4519-8979-a8e72cb00a1f"></a><a name="section-3.9.9"></a><p></p>
<h3><span class="Bold"><span class="Italics">â€œOtherâ€? bacteria</span></span></h3>
<p class="First"><span class="Italics"> Ureaplasma urealyticum</span></p>
<p><span class="Italics"> Legionella pneumophila</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e8a85784-f53b-4f17-9929-d63c0fec28e5"></a><a name="section-3.9.9.1"></a><p></p>
<h4><span class="Bold">Susceptibility Testing Methods</span></h4>
<p class="First">When available, the results of <span class="Italics">in vitro </span>susceptibility test results for antimicrobial drugs used in resident hospitals should be provided to the physician as periodic reports which describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports may differ from susceptibility data obtained from outpatient use, but could aid the physician in selecting the most effective antimicrobial.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cc64ff0c-c388-4f8b-a057-1c03e8c786b3"></a><a name="section-3.9.9.2"></a><p></p>
<h4><span class="Bold">Dilution Techniques</span></h4>
<p class="First">Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method<span class="Sup">1,2</span> (broth or agar) or equivalent with standardized inoculum concentration and standardized concentration of azithromycin powder. The MIC values should be interpreted according to criteria provided in <span class="Bold">Table 3</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e811082f-ad57-4df7-9019-ec9668103ab8"></a><a name="section-3.9.9.3"></a><p></p>
<h4><span class="Bold">Diffusion Techniques</span></h4>
<p class="First">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2,3</span> requires the use of standardized inoculum concentration. This procedure uses paper disks impregnated with 15 mcg azithromycin to test the susceptibility of bacteria to azithromycin. The disk diffusion interpretive criteria are provided in <span class="Bold">Table 3</span>.</p>
<a name="_Refid_ab369cf6-e53d-4df5-af9c-ccf3af962"></a><table width="100%">
<caption><span>Table 3. Susceptibility Test Interpretive Criteria for Azithromycin                      Susceptibility Test Result Interpretive Criteria</span></caption>
<col width="26%">
<col width="22%">
<col width="12%">
<col width="14%">
<col width="7%">
<col width="11%">
<col width="7%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Insufficient information is available to determine Intermediate or Resistant interpretive criteria </dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2"><p class="First"><span class="Bold">Pathogen</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" rowspan="1"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span> (mcg/mL)</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3">
<p class="First"><span class="Bold">Disk Diffusion</span></p>
<p><span class="Bold">(zone diameters in mm)</span></p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"></td></tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">S</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">I</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">R</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">S</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">I</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">R</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Haemophilus influenzae</span>Â <a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">â‰¤ 4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">--</p></td>
<td class="Botrule Rrule" align="center"><p class="First">--</p></td>
<td class="Botrule Rrule" align="center"><p class="First">â‰¥ 12</p></td>
<td class="Botrule Rrule" align="center"><p class="First">--</p></td>
<td class="Botrule Rrule" align="center"><p class="First">--</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">Staphylococcus aureus</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">â‰¤ 2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">â‰¥ 8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">â‰¥ 18</p></td>
<td class="Botrule Rrule" align="center"><p class="First">14 to 17</p></td>
<td class="Botrule Rrule" align="center"><p class="First">â‰¤ 13</p></td>
</tr>
<tr>
<td class="Lrule Rrule">
<p class="First">Streptococci including</p>
<p><span class="Italics">S. pneumoniae</span></p>
</td>
<td class="Rrule" align="center"><p class="First"><span class="Bold">Â </span> â‰¤ 0.5</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
<td class="Rrule" align="center"><p class="First">â‰¥ 2</p></td>
<td class="Rrule" align="center"><p class="First">â‰¥ 18</p></td>
<td class="Rrule" align="center"><p class="First">14 to 17</p></td>
<td class="Rrule" align="center"><p class="First">â‰¤ 13</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="7"><p class="First">Susceptibility to azithromycin must be tested in ambient air.</p></td></tr>
</tbody>
</table>
<p>The ability to correlate MIC values and plasma drug levels is difficult as azithromycin concentrates in macrophages and tissues (see <span class="Bold"><a href="#i4i_clinical_pharmacology_id_e07c9209-7877-418f-b1ce-8f7c3df4ece4">Clinical Pharmacology</a></span>).</p>
<p>A report of â€œsusceptibleâ€? indicates that the pathogen is likely to be inhibited if the antimicrobial compound reaches the concentrations usually achievable. A report of â€œintermediateâ€? indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of â€œresistantâ€? indicates that the pathogen is not likely to be inhibited if the antimicrobial compound reaches the concentrations usually achievable; other therapy should be selected.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_61e0f81a-7140-492f-b24e-e36ed8868d5e"></a><a name="section-3.9.10"></a><p></p>
<h3><span class="Bold"><span class="Italics"><span class="Underline">Quality Control</span></span></span></h3>
<p class="First">Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individual performing the test. Standard azithromycin powder should provide the following range of MIC values noted in <span class="Bold">Table 4</span>. For the diffusion technique using the azithromycin 15 mcg disk, the criteria in <span class="Bold">Table 4</span> should be achieved.</p>
<a name="_Refid_c6e7dedc-feb3-4172-a667-93acb3b13"></a><table width="100%">
<caption><span>Table 4. Acceptable Quality Control Ranges for Azithromycin</span></caption>
<col width="33%">
<col width="44%">
<col width="23%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>ATCC = American Type Culture Collection</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span></span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span> (mcg/mL)</span></p></td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Disk Diffusion</span></p>
<p><span class="Bold">(zone diameters in mm)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Italics">Haemophilus influenzae</span></p>
<p>ATCC<a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a> 49247</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">1 to 4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">13 to 21</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Italics">Staphylococcus aureus</span> ATCC 29213</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.5 to 2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">â€¢â€¢â€¢</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Italics">Staphylococcus aureus</span></p>
<p>ATCC 25923</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">â€¢â€¢â€¢</p></td>
<td class="Botrule Rrule" align="center"><p class="First">21 to 26</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center">
<p class="First"><span class="Italics">Streptococcus pneumoniae</span></p>
<p>ATCC 49619</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">0.06 to 0.25</p></td>
<td class="Botrule Rrule" align="center"><p class="First">19 to 25</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="3"><p class="First">Susceptibility to azithromycin must be tested in ambient air</p></td></tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_b7d8c67f-6ac6-49d6-ac4f-d30514926001"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Azithromycin for oral suspension USP is indicated for the treatment of patients with mild to moderate <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>: see <span class="Bold"><a href="#i4i_warnings_id_c369266d-c9a3-490f-9cc6-fe176181b16c">WARNINGS</a></span>) caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, please see <span class="Bold"><a href="#i4i_dosage_admin_id_5f9a39bc-e310-40e9-87ca-c4002c87c14d">DOSAGE AND ADMINISTRATION</a></span> for specific dosing recommendations.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_02b2739e-a0f0-4dba-9ac6-873d4ea7c5ea"></a><a name="section-4.1"></a><p></p>
<h2>Adults</h2>
<p class="First"><span class="Bold">Acute bacterial exacerbations of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> </span>due to <span class="Italics">Haemophilus influenzae, Moraxella catarrhalis </span>or <span class="Italics">Streptococcus pneumoniae.</span></p>
<p><span class="Bold">Acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> </span>due to <span class="Italics">Haemophilus influenzae, Moraxella catarrhalis </span>or <span class="Italics">Streptococcus pneumoniae</span>.</p>
<p><span class="Bold">Community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> </span>due to <span class="Italics">Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae </span>or <span class="Italics">Streptococcus pneumoniae </span>in patients appropriate for oral therapy.</p>
<p><span class="Bold">NOTE: Azithromycin should not be used in patients with <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following:</span></p>
<p><span class="Bold"> patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>,</span></p>
<p><span class="Bold"> patients with nosocomially acquired <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>,</span></p>
<p><span class="Bold"> patients with known or suspected <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>,</span></p>
<p><span class="Bold"> patients requiring hospitalization,</span></p>
<p><span class="Bold"> elderly or debilitated patients, or</span></p>
<p><span class="Bold"> patients with significant underlying health problems that may compromise their ability </span></p>
<p><span class="Bold"> to respond to their illness (including <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> or functional <span class="product-label-link" type="condition" conceptid="45768671" conceptname="Asplenia">asplenia</span>).</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> </span>caused by <span class="Italics">Streptococcus pyogenes </span>as an alternative to first-line therapy in individuals who cannot use first-line therapy.</p>
<p>NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of <span class="Italics"> Streptococcus pyogenes </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the prophylaxis of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>. Azithromycin for oral suspension USP is often effective in theÂ  eradication of susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Streptococcus pyogenes </span>from the nasopharynx. Because someÂ  <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are resistant to azithromycin for oral suspension USP, susceptibility tests should be performed when patients are treated with azithromycin for oral suspension USP. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic feverÂ are not available.</p>
<p><span class="Bold">Uncomplicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> </span>due to <span class="Italics">Staphylococcus aureus, Streptococcus pyogenes, </span>or <span class="Italics">Streptococcus agalactiae. </span><span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscesses</span> usually require surgical drainage.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">Urethritis</span> and <span class="product-label-link" type="condition" conceptid="196163" conceptname="Cervicitis and endocervicitis">cervicitis</span> </span>due to <span class="Italics">Chlamydia trachomatis </span>or <span class="Italics">Neisseria gonorrhoeae</span>.</p>
<p><span class="Bold">Genital <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease </span>in men due to <span class="Italics">Haemophilus ducreyi </span>(<span class="product-label-link" type="condition" conceptid="138973" conceptname="Chancroid">chancroid</span>). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of <span class="product-label-link" type="condition" conceptid="138973" conceptname="Chancroid">chancroid</span> in women has not been established.</p>
<p>Azithromycin for oral suspension USP, at the recommended dose, should not be relied upon to treat <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> may mask or delay the symptoms of incubating <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>. All patients with sexually-transmitted <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> or <span class="product-label-link" type="condition" conceptid="196163" conceptname="Cervicitis and endocervicitis">cervicitis</span> should have a serologic test for <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> and appropriate cultures for <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is confirmed.</p>
<p>Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin, USP. Therapy with azithromycin for oral suspension USP may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin for oral suspension USP and other antibacterial drugs, azithromycin for oral suspension USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_17b4acd3-e3f5-4833-869e-25d450c8f052"></a><a name="section-4.2"></a><p></p>
<h2>Pediatric Patients </h2>
<p class="First">See <span class="Bold">PRECAUTIONS, <a href="#i4i_pediatric_use_id_185a14d9-8f7f-47e0-adf0-f361468c8b03">Pediatric Use</a></span> and <span class="Bold"><a href="#i4i_clinical_studies_id_4b74d96a-0f10-4ff9-9535-f64f5e3961ad">CLINICAL STUDIES, Pediatric Patients. </a></span></p>
<p><span class="Bold">Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span></span>Â  caused by <span class="Italics">Haemophilus influenzae, Moraxella catarrhalis </span>or <span class="Italics">StreptococcusÂ pneumoniae. </span>(For specific dosage recommendation, see <span class="Bold"><a href="#i4i_dosage_admin_id_5f9a39bc-e310-40e9-87ca-c4002c87c14d">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p><span class="Bold">Community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> </span>due to <span class="Italics">Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae </span>or <span class="Italics">Streptococcus pneumoniae </span>in patients appropriate for oral therapy. (For specific dosageÂ  recommendation, see <span class="Bold"><a href="#i4i_dosage_admin_id_5f9a39bc-e310-40e9-87ca-c4002c87c14d">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p><span class="Bold">NOTE: Azithromycin should not be used in pediatric patients with <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following:</span></p>
<p><span class="Bold"> patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>,</span></p>
<p><span class="Bold"> patients with nosocomially acquired <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>,</span></p>
<p><span class="Bold"> patients with known or suspected <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>,</span></p>
<p><span class="Bold"> patients requiring hospitalization, or</span></p>
<p><span class="Bold"> patients with significant underlying health problems that may compromise their ability </span></p>
<p><span class="Bold"> to respond to their illness (including <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> or functional <span class="product-label-link" type="condition" conceptid="45768671" conceptname="Asplenia">asplenia</span>).</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> </span>caused by <span class="Italics">Streptococcus pyogenes </span>as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see <span class="Bold"><a href="#i4i_dosage_admin_id_5f9a39bc-e310-40e9-87ca-c4002c87c14d">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p>NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of <span class="Italics">Streptococcus pyogenes </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the prophylaxis of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>. Azithromycin for oral suspension USP is often effective in the eradication of susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Streptococcus pyogenes </span>from the nasopharynx. Because someÂ  <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are resistant to azithromycin for oral suspension USP, susceptibility tests should be performed when patients are treatedÂ with azithromycin for oral suspension USP. Data establishing efficacy of azithromycin in subsequent prevention of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> are not available.</p>
<p>Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin for oral suspension USP may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_6bff67ec-7d64-48e7-a415-4a7e9a406728"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Azithromycin is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to azithromycin, erythromycin any macrolide or ketolide antibiotic. Azithromycin is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>/hepatic dysfunction associated with prior use of azithromycin.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_c369266d-c9a3-490f-9cc6-fe176181b16c"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c359b9bc-5859-44c6-990a-d6da6ce889af"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, and dermatologic reactions including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have been reported rarely in patients on azithromycin therapy. Although rare, fatalities have been reported (see <span class="Bold"><a href="#i4i_contraindications_id_6bff67ec-7d64-48e7-a415-4a7e9a406728">CONTRAINDICATIONS</a></span>). Despite initially successful symptomatic treatment of the allergic symptoms, when symptomatic therapy was discontinued, the allergic symptoms <span class="Bold">recurred soon thereafter in some patients without further azithromycin exposure. </span>These patients required <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of observation and symptomatic treatment. The relationship of these episodes to the long tissue half-life of azithromycin and subsequent prolonged exposure to antigen is unknown at present.</p>
<p>If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> occurs, the drug should be discontinued and appropriate therapy should be instituted. Physicians should be aware that reappearance of the allergic symptoms may occur when symptomatic therapy is discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b48b23eb-e330-42e5-bd9e-de008910d8c6"></a><a name="section-6.2"></a><p></p>
<h2>Hepatotoxicity</h2>
<p class="First">Abnormal liver function, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> have been reported, some of which have resulted in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Discontinue azithromycin immediately if signs and symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_19e51f8b-dc74-41bb-8e22-eee4d63c1d69"></a><a name="section-6.3"></a><p></p>
<h2>Treatment of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></h2>
<p class="First"><span class="Bold">In the treatment of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, azithromycin has only been shown to be safe and effective in the treatment of community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> due to <span class="Italics">Chlamydia pneumoniae, Haemophilusinfluenzae, Mycoplasma pneumoniae </span>or <span class="Italics">Streptococcus pneumoniae </span>in patients appropriate for oral therapy. Azithromycin should not be used in patients with <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of thefollowing: patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>, patients with nosocomially acquired <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, patients with known or suspected <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond totheir illness (including <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> or functional <span class="product-label-link" type="condition" conceptid="45768671" conceptname="Asplenia">asplenia</span>).</span></p>
<p><span class="Bold"><span class="Italics">Clostridium Difficile-</span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span></p>
<p><span class="Italics">Clostridium difficile-</span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including azithromycin, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>. </p>
<p><span class="Italics">C. difficile </span>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile </span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. </p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile </span>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6fcdcf09-abfc-433d-b015-6dbdaedec0a5"></a><a name="section-6.4"></a><p></p>
<h2>QT Prolongation</h2>
<p class="First">Prolonged cardiac repolarization and QT interval, imparting a risk of developing <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span> and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>, have been seen in treatment with macrolides, including azithromycin. Cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> have been spontaneously reported during postmarketing surveillance in patients receiving azithromycin. Providers should consider the risk of QT prolongation which can be fatal when weighing the risks and benefits of azithromycin for at-risk groups including:</p>
<dl>
<dt>â€¢</dt>
<dd>patients with known prolongation of the QT interval, a history of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>, congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>, <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span> or uncompensated <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></dd>
<dt>â€¢</dt>
<dd>patients on drugs known to prolong the QT interval</dd>
<dt>â€¢</dt>
<dd>patients with ongoing proarrhythmic conditions such as uncorrected <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, clinically significant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.</dd>
</dl>
<p>Elderly patients may be more susceptible to drug-associated effects on the QT interval.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_8f286d79-be67-4033-8c9e-8386d50938fd"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_a43f82a8-fc9a-45d5-8730-d3489bbeeec6"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Because azithromycin is principally eliminated via the liver, caution should be exercised when azithromycin is administered to patients with impaired hepatic function. Due to the limited data in subjects with GFR &lt; 10 mL/min, caution should be exercised when prescribing azithromycin in these patients (see <span class="Bold">CLINICAL PHARMACOLOGY, Special Populations, </span><span class="Italics"><a href="#i4i_section_id_83080b33-9c49-4aeb-b0c8-14465551e261">Renal</a><a href="#i4i_section_id_83080b33-9c49-4aeb-b0c8-14465551e261">Insufficiency</a></span>).</p>
<p>Exacerbation of symptoms of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> and new onset of <span class="product-label-link" type="condition" conceptid="4237155" conceptname="Eaton-Lambert syndrome">myasthenic syndrome</span> have been reported in patients receiving azithromycin therapy.</p>
<p>Prescribing azithromycin in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_b7040fc9-ba4f-49bd-b56c-91433247f687"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Azithromycin for oral suspension can be taken with or without food.</p>
<p>Patients should also be cautioned not to take aluminum- and magnesium-containing antacids and azithromycin simultaneously.</p>
<p>The patient should be directed to discontinue azithromycin immediately and contact a physician if any signs of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> occur.</p>
<p>Patients should be counseled that antibacterial drugs including azithromycin should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When azithromycin is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of the therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by azithromycin or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_4abb8a91-5a4d-4267-b492-1d6e24f96db1"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Coadministration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations. Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted (see <span class="Bold"><a href="#i4i_adverse_effects_id_7511c562-44a3-46e1-8b4c-b8c53d4f62d3">ADVERSE REACTIONS</a></span>).</p>
<p>Although, in a study of 22 healthy men, a 5 day course of azithromycin did not affect the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time from a subsequently administered dose of warfarin, spontaneous postmarketing reports suggest that concomitant administration of azithromycin may potentiate the effects of oral anticoagulants. <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants concomitantly.</p>
<p>Drug interaction studies were performed with azithromycin and other drugs likely to be coadministered (see <span class="Bold">CLINICAL PHARMACOLOGY, <a href="#i4i_section_id_b8a30bfd-6927-4543-b281-58f1a0a6af20">Drug-Drug Interactions</a></span>). When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine. Coadministration with efavirenz, or fluconazole had a modest effect on the pharmacokinetics of azithromycin. No dosage adjustment of either drug is recommended when azithromycin is coadministered with any of the above agents.</p>
<p>Interactions with the drugs listed below have not been reported in clinical trials with azithromycin; however, no specific drug interaction studies have been performed to evaluate potential drug-drug interaction. Nonetheless, they have been observed with macrolide products. Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised:</p>
<p>Digoxinâ€“elevated digoxin concentrations.</p>
<p>Ergotamine or dihydroergotamineâ€“acute ergot toxicity characterized by severe peripheral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> and <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>.</p>
<p>Terfenadine, cyclosporine, hexobarbital and phenytoin concentrations.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_0850510f-6c4b-45b9-a10d-d56f8071e3c1"></a><a name="section-7.4"></a><p></p>
<h2>Laboratory Test Interactions</h2>
<p class="First">There are no reported laboratory test interactions.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_ffabe16f-b158-43ec-b279-807fc77f3528"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals have not been performed to evaluate carcinogenic potential. Azithromycin has shown no mutagenic potential in standard laboratory tests: mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, human lymphocyte clastogenic assay, and mouse bone marrow clastogenic assay. No evidence of impaired fertility due to azithromycin was found.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_23462828-fc17-4312-8ae3-6184e29a8458"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_84347059-1d4f-4160-b9db-42e47358def3"></a><a name="section-7.6.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects</span></h3>
<p class="First"><span class="Italics">Pregnancy Category B</span></p>
<p>Reproduction studies have been performed in rats and mice at doses up to moderately maternally toxic dose concentrations (i.e., 200 mg/kg/day). These doses, based on a mg/m<span class="Sup">2</span> basis, are estimated to be 4 and 2 times, respectively, the human daily dose of 500 mg. In the animal studies, no evidence of harm to the fetus due to azithromycin was found. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, azithromycin should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_61ca1451-eb8d-4f22-bf69-5c519edb13b5"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether azithromycin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when azithromycin is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_185a14d9-8f7f-47e0-adf0-f361468c8b03"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">See <span class="Bold"><a href="#i4i_clinical_pharmacology_id_e07c9209-7877-418f-b1ce-8f7c3df4ece4">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_indications_id_b7d8c67f-6ac6-49d6-ac4f-d30514926001">INDICATIONS AND USAGE</a>, </span>and <span class="Bold"><a href="#i4i_dosage_admin_id_5f9a39bc-e310-40e9-87ca-c4002c87c14d">DOSAGE AND ADMINISTRATION</a>.</span></p>
<p>Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> (total dosage regimen: 30 mg/kg, see <span class="Bold"><a href="#i4i_dosage_admin_id_5f9a39bc-e310-40e9-87ca-c4002c87c14d">DOSAGE AND ADMINISTRATION</a></span>): Safety and effectiveness in the treatment of pediatric patients with <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> under 6 months of age have not been established.</p>
<p>Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> (dosage regimen: 10 mg/kg on Days 1 to 3): Safety and effectiveness in the treatment of pediatric patients with acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> under 6 months of age have not been established. Use of azithromycin for the treatment of acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> in pediatric patients (6 months of age or greater) is supported by adequate and well-controlled studies in adults, similar pathophysiology of <span class="product-label-link" type="condition" conceptid="260123" conceptname="Acute sinusitis">acute sinusitis</span> in adults and pediatric patients, and studies of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> in pediatric patients.</p>
<p>Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> (dosage regimen: 10 mg/kg on Day 1 followed by 5 mg/kg on Days 2 to 5): Safety and effectiveness in the treatment of pediatric patients with community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> under 6 months of age have not been established. Safety and effectiveness for <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> due to <span class="Italics">Chlamydophilapneumoniae </span>and <span class="Italics">Mycoplasma pneumoniae </span>were documented in pediatric clinical trials. Safety and effectiveness for <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> due to <span class="Italics">Haemophilus influenzae </span>and <span class="Italics">Streptococcus pneumoniae </span>were not documented bacteriologically in the pediatric clinical trial due to difficulty in obtaining specimens. Use of azithromycin for these two microorganisms is supported, however, by evidence from adequate and well-controlled studies in adults.</p>
<p><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span> (dosage regimen: 12 mg/kg on Days 1 to 5): Safety and effectiveness in the treatment of pediatric patients with <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> under 2 years of age have not been established. Â </p>
<p><span class="Bold">Studies evaluating the use of repeated courses of therapy have not been conducted </span>(see <span class="Bold"><a href="#i4i_clinical_pharmacology_id_e07c9209-7877-418f-b1ce-8f7c3df4ece4">CLINICAL PHARMACOLOGY </a></span>and <span class="Bold"><a href="#i4i_animal_pharmacology_id_46c52494-6d09-44a9-8788-1bcdcd10c642">ANIMAL TOXICOLOGY</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_1b60ccc6-2287-499c-bfbd-0b68711343ee"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Pharmacokinetic parameters in older volunteers (65 to 85 years old) were similar to those in younger volunteers (18 to 40 years old) for the 5 day therapeutic regimen. Dosage adjustment does not appear to be necessary for older patients with normal renal and hepatic function receiving treatment with this dosage regimen (see <span class="Bold"><a href="#i4i_clinical_pharmacology_id_e07c9209-7877-418f-b1ce-8f7c3df4ece4">CLINICAL PHARMACOLOGY</a></span>).</p>
<p>In multiple-dose clinical trials of oral azithromycin, 9% of patients were at least 65 years of age (458/4949) and 3% of patients (144/4949) were at least 75 years of age. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in response between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>Elderly patients may be more susceptible to development of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> than younger patients (see <span class="Bold"><a href="#i4i_warnings_id_c369266d-c9a3-490f-9cc6-fe176181b16c">WARNINGS</a></span>).</p>
<p>Azithromycin for oral suspension USP, 100 mg/5 mL contains 8.8 mg of sodium per 5 mL of constituted solution.</p>
<p>Azithromycin for oral suspension USP, 200 mg/5 mL contains 8.8 mg of sodium per 5 mL of constituted solution.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_7511c562-44a3-46e1-8b4c-b8c53d4f62d3"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">In clinical trials, most of the reported side effects were mild to moderate in severity and were reversible upon discontinuation of the drug. Potentially serious side effects of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> were reported rarely. Approximately 0.7% of the patients (adults and pediatric patients) from the 5 day multiple-dose clinical trials discontinued azithromycin therapy because of treatment-related side effects. In adults given 500 mg/day for 3 days, the discontinuation rate due to treatment-related side effects was 0.6%. In clinical trials in pediatric patients given 30 mg/kg, either as a single dose or over 3 days, discontinuation from the trials due to treatment-related side effects was approximately 1% (see <span class="Bold"><a href="#i4i_dosage_admin_id_5f9a39bc-e310-40e9-87ca-c4002c87c14d">DOSAGE AND ADMINISTRATION</a></span>). Most of the side effects leading to discontinuation were related to the gastrointestinal tract, e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (see <span class="Bold"><a href="#i4i_clinical_studies_id_4b74d96a-0f10-4ff9-9535-f64f5e3961ad">CLINICAL STUDIES, Pediatric Patients </a></span>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d769e484-c875-40ef-9ea0-68721fecf28d"></a><a name="section-8.1"></a><p></p>
<h2>Clinical</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e400ebd5-20e6-4f82-8bc1-046f23988e20"></a><a name="section-8.1.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Adults</span></span></h3>
<p class="First"><span class="Italics">Multiple-dose regimens: </span>Overall, the most common treatment-related side effects in adult patients receiving multiple-dose regimens of azithromycin were related to the gastrointestinal system with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (4 to 5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3%) and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (2 to 3%) being the most frequently reported.</p>
<p>No other treatment-related side effects occurred in patients on the multiple-dose regimens of azithromycin with a frequency greater than 1%. Side effects that occurred with a frequency of 1% or less included the following:</p>
<p><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>.</p>
<p><span class="Bold">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span> and <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>.</p>
<p><span class="Bold">Genitourinary: </span>Monilia, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> and <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>.</p>
<p><span class="Bold">Nervous System: </span><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.</p>
<p><span class="Bold">General: </span><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>.</p>
<p><span class="Bold">Allergic: </span><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p><span class="Italics">Single 1 gram dose regimen: </span>Overall, the most common side effects in patients receiving a single-dose regimen of 1 gram of azithromycin were related to the gastrointestinal system and were more frequently reported than in patients receiving the multiple-dose regimen.</p>
<p>Side effects that occurred in patients on the single one-gram dosing regimen of azithromycin with a frequency of 1% or greater included <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (7%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (5%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (5%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (2%), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (1%) and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> (1%).</p>
<p><span class="Italics">Single 2 gram dose regimen: </span>Overall, the most common side effects in patients receiving a single 2 gram dose of azithromycin were related to the gastrointestinal system. Side effects that occurred in patients in this study with a frequency of 1% or greater included <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (18%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (14%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (7%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (7%), <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> (2%), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (1%) and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (1%). The majority of these complaints were mild in nature.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b5e56544-f1b7-4e1e-b027-a0ef2d6662d9"></a><a name="section-8.2"></a><p></p>
<h2>Pediatric Patients</h2>
<p class="First"><span class="Italics">Single- and Multiple-dose regimens: </span>The types of side effects in pediatric patients were comparable to those seen in adults, with different incidence rates for the dosage regimens recommended in pediatric patients.</p>
<p>Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span>: For the recommended total dosage regimen of 30 mg/kg, the most frequent side effects (â‰¥ 1%) attributed to treatment were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (see <span class="Bold"><a href="#i4i_dosage_admin_id_5f9a39bc-e310-40e9-87ca-c4002c87c14d">DOSAGE AND ADMINISTRATION </a></span>and <span class="Bold"><a href="#i4i_clinical_studies_id_4b74d96a-0f10-4ff9-9535-f64f5e3961ad">CLINICAL STUDIES, Pediatric Patients</a></span>).</p>
<p>The incidence, based on dosing regimen, is described in the table below:</p>
<table width="100%">
<col width="11%">
<col width="13%">
<col width="13%">
<col width="14%">
<col width="12%">
<col width="10%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2">
<p class="First">Dosage</p>
<p>Regimen</p>
</td>
<td class="Botrule Rrule Toprule" rowspan="2"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, %</p></td>
<td class="Botrule Rrule Toprule" rowspan="2">
<p class="First">Abdominal</p>
<p><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, %</p>
</td>
<td class="Botrule Rrule Toprule" rowspan="2"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>, %</p></td>
<td class="Botrule Rrule Toprule" rowspan="2"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, %</p></td>
<td class="Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, %</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule"></td></tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">1 day</p></td>
<td class="Botrule Rrule"><p class="First">4.3%</p></td>
<td class="Botrule Rrule"><p class="First">1.4%</p></td>
<td class="Botrule Rrule"><p class="First">4.9%</p></td>
<td class="Botrule Rrule"><p class="First">1%</p></td>
<td class="Botrule Rrule"><p class="First">1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">3 day</p></td>
<td class="Botrule Rrule"><p class="First">2.6%</p></td>
<td class="Botrule Rrule"><p class="First">1.7%</p></td>
<td class="Botrule Rrule"><p class="First">2.3%</p></td>
<td class="Botrule Rrule"><p class="First">0.4%</p></td>
<td class="Botrule Rrule"><p class="First">0.6%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">5 day</p></td>
<td class="Botrule Rrule"><p class="First">1.8%</p></td>
<td class="Botrule Rrule"><p class="First">1.2%</p></td>
<td class="Botrule Rrule"><p class="First">1.1%</p></td>
<td class="Botrule Rrule"><p class="First">0.5%</p></td>
<td class="Botrule Rrule"><p class="First">0.4%</p></td>
</tr>
</tbody>
</table>
<p>Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: For the recommended dosage regimen of 10 mg/kg on Day 1 followed by 5 mg/kg on Days 2 to 5, the most frequent side effects attributed to treatment were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p>The incidence is described in the table below:</p>
<table width="100%">
<col width="18%">
<col width="26%">
<col width="20%">
<col width="14%">
<col width="12%">
<col width="10%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2"><p class="First">Dosage Regimen</p></td>
<td class="Botrule Rrule Toprule" rowspan="2"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Loose stools</span>, %</p></td>
<td class="Botrule Rrule Toprule" rowspan="2"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span>, %</p></td>
<td class="Botrule Rrule Toprule" rowspan="2"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>, %</p></td>
<td class="Botrule Rrule Toprule" rowspan="2"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, %</p></td>
<td class="Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, %</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule"></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">5 day</p></td>
<td class="Botrule Rrule"><p class="First">5.8%</p></td>
<td class="Botrule Rrule"><p class="First">1.9%</p></td>
<td class="Botrule Rrule"><p class="First">1.9%</p></td>
<td class="Botrule Rrule"><p class="First">1.9%</p></td>
<td class="Botrule Rrule"><p class="First">1.6%</p></td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span>: For the recommended dosage regimen of 12 mg/kg on Days 1 to 5, the most frequent side effects attributed to treatment were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p>The incidence is described in the table below:</p>
<table width="100%">
<col width="17%">
<col width="13%">
<col width="20%">
<col width="14%">
<col width="12%">
<col width="10%">
<col width="14%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2"><p class="First">Dosage Regimen</p></td>
<td class="Botrule Rrule Toprule" rowspan="2"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, %</p></td>
<td class="Botrule Rrule Toprule" rowspan="2"><p class="First">AbdominalPain, %</p></td>
<td class="Botrule Rrule Toprule" rowspan="2"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>, %</p></td>
<td class="Botrule Rrule Toprule" rowspan="2"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, %</p></td>
<td class="Botrule Rrule Toprule" rowspan="2"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, %</p></td>
<td class="Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, %</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule"></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">5 day</p></td>
<td class="Botrule Rrule"><p class="First">5.4%</p></td>
<td class="Botrule Rrule"><p class="First">3.4%</p></td>
<td class="Botrule Rrule"><p class="First">5.6%</p></td>
<td class="Botrule Rrule"><p class="First">1.8%</p></td>
<td class="Botrule Rrule"><p class="First">0.7%</p></td>
<td class="Botrule Rrule"><p class="First">1.1%</p></td>
</tr>
</tbody>
</table>
<p>With any of the treatment regimens, no other treatment-related side effects occurred in pediatric patients treated with azithromycin with a frequency greater than 1%. Side effects that occurred with a frequency of 1% or less included the following:</p>
<p><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>.</p>
<p><span class="Bold">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> and <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral moniliasis</span>.</p>
<p><span class="Bold">Hematologic and Lymphatic: </span><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>.</p>
<p><span class="Bold">Nervous System: </span><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> (<span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> dosage), <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
<p><span class="Bold">General: </span><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p><span class="Bold">Allergic: </span><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
<p><span class="Bold">Respiratory: </span><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough increased</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> and <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>.</p>
<p><span class="Bold">Skin and Appendages: </span><span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Eczema</span>, <span class="product-label-link" type="condition" conceptid="137213" conceptname="Dermal mycosis">fungal dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">vesiculobullous rash</span>.</p>
<p><span class="Bold">Special Senses: </span><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_faca1fe4-6b2c-4fe4-a7f5-9a93326d96ff"></a><a name="section-8.3"></a><p></p>
<h2>Postmarketing Experience</h2>
<p class="First">Adverse events reported with azithromycin during the postmarketing period in adult and/or pediatric patients for which a causal relationship may not be established include:</p>
<p><span class="Bold">Allergic: </span><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. There have been rare reports of QT prolongation and <span class="Italics"><span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span></span>.</p>
<p><span class="Bold">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> rarely resulting in <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral candidiasis</span>, <span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">pyloric stenosis</span>, and rare reports of <span class="product-label-link" type="condition" conceptid="4217621" conceptname="Black hairy tongue">tongue discoloration</span>.</p>
<p><span class="Bold">General: </span><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> (rarely fatal).</p>
<p><span class="Bold">Genitourinary: </span>Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>.</p>
<p><span class="Bold">Hematopoietic: </span><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>.</p>
<p><span class="Bold">Liver/Biliary: </span>Adverse reactions related to hepatic dysfunction have been reported in</p>
<p>postmarketing experience with azithromycin (see <span class="Bold">WARNINGS, Hepatotoxicity</span>).</p>
<p><span class="Bold">Nervous System: </span><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p><span class="Bold">Psychiatric: </span><span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggressive reaction</span> and <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>.</p>
<p><span class="Bold">Skin/Appendages: </span><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, rarely serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> including <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>.</p>
<p><span class="Bold">Special Senses: </span>Hearing disturbances including <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span> and/or <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> and reports of taste/<span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">smell perversion</span> and/or loss.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8c09db49-2bb2-4445-a5a1-55552dc46235"></a><a name="section-8.4"></a><p></p>
<h2>Laboratory Abnormalities</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9fdca6c2-5708-48c1-b842-ba9a77961a14"></a><a name="section-8.4.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Adults</span></span></h3>
<p class="First">Clinically significant abnormalities (irrespective of drug relationship) occurring during the clinical trials were reported as follows: with an incidence of greater than 1%: <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">decreased hemoglobin</span>, hematocrit, <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> and blood glucose; elevated serum creatine phosphokinase, potassium, ALT, GGT, AST, BUN, creatinine, blood glucose, platelet count, <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> and eosinophils; with an incidence of less than 1%: <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, decreased sodium, potassium, platelet count, elevated monocytes, <span class="product-label-link" type="condition" conceptid="4172647" conceptname="Basophil count">basophils</span>, <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, serum alkaline phosphatase, bilirubin, LDH and phosphate. The majority of subjects with elevated serum creatinine also had abnormal values at baseline.</p>
<p>When follow-up was provided, changes in laboratory tests appeared to be reversible.</p>
<p>In multiple-dose clinical trials involving more than 5000 patients, four patients discontinued therapy because of treatment-related liver enzyme abnormalities and one because of a renal function abnormality.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4e79b488-8729-4114-8ef8-b6afcf57786f"></a><a name="section-8.4.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Pediatric Patients</span></span></h3>
<p class="First"><span class="Bold">One, Three and Five Day Regimens</span></p>
<p>Laboratory data collected from comparative clinical trials employing two 3 day regimens (30 mg/kg or 60 mg/kg in divided doses over 3 days), or two 5 day regimens (30 mg/kg or 60 mg/kg in divided doses over 5 days) were similar for regimens of azithromycin and all comparators combined, with most clinically significant laboratory abnormalities occurring at incidences of 1 to 5%. Laboratory data for patients receiving 30 mg/kg as a single dose were collected in one single center trial. In that trial, an absolute neutrophil count between 500 to 1500 cells/mm<span class="Sup">3</span> was observed in 10/64 patients receiving 30 mg/kg as a single dose, 9/62 patients receiving 30 mg/kg given over 3 days, and 8/63 comparator patients. No patient had an absolute neutrophil count &lt; 500 cells/mm<span class="Sup">3</span> (see <span class="Bold"><a href="#i4i_dosage_admin_id_5f9a39bc-e310-40e9-87ca-c4002c87c14d">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>In multiple-dose clinical trials involving approximately 4700 pediatric patients, no patients discontinued therapy because of treatment-related laboratory abnormalities.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_5f9a39bc-e310-40e9-87ca-c4002c87c14d"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">See <span class="Bold"><a href="#i4i_indications_id_b7d8c67f-6ac6-49d6-ac4f-d30514926001">INDICATIONS AND USAGE</a></span> and <span class="Bold"><a href="#i4i_clinical_pharmacology_id_e07c9209-7877-418f-b1ce-8f7c3df4ece4">CLINICAL PHARMACOLOGY</a></span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9c7a1205-87a9-4841-b0d8-29579016f1fd"></a><a name="section-9.1"></a><p></p>
<h2>Adults</h2>
<table width="100%">
<col width="66%">
<col width="34%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="2" valign="top">
<span class="Bold">*DUE TO THE INDICATED ORGANISMS</span> (see<span class="Bold"><a href="#i4i_indications_id_b7d8c67f-6ac6-49d6-ac4f-d30514926001"> INDICATIONS AND USAGE</a></span>).</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>* </p></td>
<td class="Botrule Rrule Toprule"><p class="First">Recommended Dose/Duration of Therapy</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">
<p class="First">Community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (mild severity) </p>
<p><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> (second line therapy) </p>
<p>Skin/skin structure (uncomplicated)</p>
</td>
<td class="Botrule Rrule">
<p class="First">500 mg as a single dose on Day 1, followed</p>
<p>by 250 mg once daily on Days 2 through 5.</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Acute bacterial exacerbations of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (mild to moderate)</p></td>
<td class="Botrule Rrule">
<p class="First">500 mg QD x 3 days</p>
<p>OR</p>
<p>500 mg as a single dose on Day 1, followed</p>
<p>by 250 mg once daily on Days 2 through 5.</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> </p></td>
<td class="Botrule Rrule"><p class="First">500 mg QD x 3 days</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Genital <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease (<span class="product-label-link" type="condition" conceptid="138973" conceptname="Chancroid">chancroid</span>)</p></td>
<td class="Botrule Rrule"><p class="First">One single 1 gram dose</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Non-gonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> and <span class="product-label-link" type="condition" conceptid="196163" conceptname="Cervicitis and endocervicitis">cervicitis</span></p></td>
<td class="Botrule Rrule"><p class="First">One single 1 gram dose</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Gonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> and <span class="product-label-link" type="condition" conceptid="196163" conceptname="Cervicitis and endocervicitis">cervicitis</span></p></td>
<td class="Botrule Rrule"><p class="First">One single 2 gram dose</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0161e90c-a1f8-4961-bc81-6577e5a4e21f"></a><a name="section-9.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h2>
<p class="First">No dosage adjustment is recommended for subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR â‰¤ 80 mL/min). The mean AUC<span class="Sub">0-120</span> was similar in subjects with GFR 10 to 80 mL/min compared to subjects with normal renal function, whereas it increased 35% in subjects with GFR &lt; 10 mL/min compared to subjects with normal renal function. Caution should be exercised when azithromycin is administered to subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <span class="Bold">CLINICAL PHARMACOLOGY, Special Populations, </span><span class="Italics"><a href="#i4i_section_id_83080b33-9c49-4aeb-b0c8-14465551e261">Renal </a><a href="#i4i_section_id_83080b33-9c49-4aeb-b0c8-14465551e261">Insufficiency</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bd91aba9-a957-4571-a581-940f4a3a78b5"></a><a name="section-9.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">The pharmacokinetics of azithromycin in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been established. No dose adjustment recommendations can be made in patients with impaired hepatic function (see <span class="Bold">CLINICALPHARMACOLOGY, Special Populations, </span><span class="Italics"><a href="#i4i_section_id_366c54af-3d22-4162-a18c-01b5d82f2bcb">Hepatic </a><a href="#i4i_section_id_366c54af-3d22-4162-a18c-01b5d82f2bcb">Insufficiency</a></span>). </p>
<p>No dosage adjustment is recommended based on age or gender (see <span class="Bold">CLINICAL PHARMACOLOGY,<a href="#i4i_section_id_a5f62d0f-9973-4144-af1c-f882a4d92fa0">Special Populations</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d151270e-e1d5-4cc9-9e85-c158264b2ef2"></a><a name="section-9.4"></a><p></p>
<h2>Pediatric Patients</h2>
<p class="First">Azithromycin for oral suspension can be taken with or without food.</p>
<p><span class="Bold">Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span>: </span>The recommended dose of azithromycin for oral suspension for the treatment of pediatric patients with acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> is 30 mg/kg given as a single dose or 10 mg/kg once daily for 3 days or 10 mg/kg as a single dose on the first day followed by 5 mg/kg/day on Days 2 through 5. (See chart below.)</p>
<p><span class="Bold">Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>: </span>The recommended dose of azithromycin for oral suspension for the treatment of pediatric patients with acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> is 10 mg/kg once daily for 3 days. (See chart below.)</p>
<p><span class="Bold">Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>: </span>The recommended dose of azithromycin for oral suspension for the treatment of pediatric patients with community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> is 10 mg/kg as a single dose on the first day followed by 5 mg/kg on Days 2 through 5. (See chart below.)</p>
<p>Â </p>
<a name="_Refid_6d178830-4617-4205-afa8-2459ee109"></a><table width="100%">
<caption><span>PEDIATRIC DOSAGE GUIDELINES FOR <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">OTITIS MEDIA</span>, ACUTE BACTERIAL <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">SINUSITIS</span> AND COMMUNITY-ACQUIRED <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">PNEUMONIA</span> (Age 6 months and above, see PRECAUTIONS, <a href="#i4i_pediatric_use_id_185a14d9-8f7f-47e0-adf0-f361468c8b03">Pediatric Use</a>.) Based on Body Weight</span></caption>
<col width="10%">
<col width="11%">
<col width="7%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="20%">
<col width="20%">
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>Effectiveness of the 3 day or 1 day regimen in pediatric patients with community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> has not been established.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="8"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">OTITIS MEDIA</span> AND COMMUNITY-ACQUIRED <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">PNEUMONIA</span>: (5 Day Regimen)</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a></p></td></tr>
<tr><td class="Botrule" align="center" colspan="8"><p class="First"><span class="Bold">Dosing Calculated on 10 mg/kg/day Day 1 and 5 mg/kg/day Days 2 to 5.</span></p></td></tr>
<tr>
<td class="Botrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">Weight</span></p></td>
<td class="Botrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">100 mg/5 mL</span></p></td>
<td class="Botrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">200 mg/5 mL</span></p></td>
<td class="Botrule Rrule" align="center" rowspan="1"><p class="First"><span class="Bold">Total mL per Treatment Course</span></p></td>
<td class="Botrule" align="center" rowspan="1"><p class="First"><span class="Bold">Total mg per Treatment Course</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Kg</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Lbs.</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Day 1</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Days 2 to 5</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Day 1</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Days 2 to 5</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Rrule" valign="bottom">
<p class="First">2.5 mL</p>
<p>(<span class="Sup">1</span>/<span class="Sub">2</span> tsp) </p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">1.25 mL (<span class="Sup">1</span>/<span class="Sub">4</span> tsp)</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First">7.5 mL</p></td>
<td class="Botrule" align="center"><p class="First">150 mg</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">10</p></td>
<td class="Botrule Rrule" align="center"><p class="First">22</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">5 mL </p>
<p>(1 tsp)</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">2.5 mL  (<span class="Sup">1</span>/<span class="Sub">2</span> tsp)</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First">15 mL</p></td>
<td class="Botrule" align="center"><p class="First">300 mg</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">20</p></td>
<td class="Botrule Rrule" align="center"><p class="First">44</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule">
<p class="First">5 mL </p>
<p>(1 tsp)</p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">2.5 mL </p>
<p>(Â½ tsp)</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">15 mL</p></td>
<td class="Botrule" align="center"><p class="First">600 mg</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">30</p></td>
<td class="Botrule Rrule" align="center"><p class="First">66</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule">
<p class="First">7.5 mL</p>
<p>(1Â½ tsp)</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">3.75 mL (Â¾ tsp)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">22.5 mL </p></td>
<td class="Botrule" align="center"><p class="First">900 mg</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">40</p></td>
<td class="Botrule Rrule" align="center"><p class="First">88</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First">10 mL (2 tsp)</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">5 mL </p>
<p>(1 tsp)</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">30 mL</p></td>
<td class="Botrule" align="center"><p class="First">1200 mg</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="center"><p class="First">50 and above</p></td>
<td class="Botrule Rrule" align="center"><p class="First">110 and above</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First">12.5 mL (2Â½ tsp)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6.25 mL (1Â¼ tsp)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">37.5 mL </p></td>
<td class="Botrule" align="center"><p class="First">1500 mg</p></td>
</tr>
</tbody>
</table>
<table width="100%">
<col width="12%">
<col width="13%">
<col width="12%">
<col width="12%">
<col width="26%">
<col width="26%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-12" href="#footnote-reference-12">*</a></dt>
<dd>Effectiveness of the 5 day or 1 day regimen in pediatric patients with acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> has not been established.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="6"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">OTITIS MEDIA</span> AND ACUTE BACTERIAL <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">SINUSITIS</span>: (3 Day Regimen)</span><a name="footnote-reference-12" href="#footnote-12" class="Sup">*</a></p></td></tr>
<tr><td class="Botrule" align="center" colspan="6"><p class="First"><span class="Bold">Dosing Calculated on 10 mg/kg/day.</span></p></td></tr>
<tr>
<td class="Botrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">Weight</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">100 mg/5 mL</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">200 mg/5 mL</span></p></td>
<td class="Botrule Rrule" rowspan="2"><p class="First"><span class="Bold">Total mL per Treatment Course</span></p></td>
<td class="Botrule" rowspan="2"><p class="First"><span class="Bold">Total mg per Treatment Course</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Kg</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Lbs.</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Day 1 to 3</span></p></td>
<td class="Botrule"><p class="First"><span class="Bold">Day 1 to 3</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">2.5 mL</p>
<p> (Â½ tsp)</p>
</td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First">7.5 mL</p></td>
<td class="Botrule" align="center"><p class="First">150 mg</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">10</p></td>
<td class="Botrule Rrule" align="center"><p class="First">22</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">5 mL </p>
<p>(1 tsp)</p>
</td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First">15 mL</p></td>
<td class="Botrule" align="center"><p class="First">300 mg</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">20</p></td>
<td class="Botrule Rrule" align="center"><p class="First">44</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First">5 mL </p>
<p>(1 tsp)</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">15 mL</p></td>
<td class="Botrule" align="center"><p class="First">600 mg</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">30</p></td>
<td class="Botrule Rrule" align="center"><p class="First">66</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">7.5 mL </p>
<p>(1Â½ tsp)</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">22.5 mL</p></td>
<td class="Botrule" align="center"><p class="First">900 mg</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">40</p></td>
<td class="Botrule Rrule" align="center"><p class="First">88</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule" align="center">
<p class="First">10 mL </p>
<p>(2 tsp)</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">30 mL</p></td>
<td class="Botrule" align="center"><p class="First">1200 mg</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">50 and above</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">110 and above</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule" align="center">
<p class="First">12.5 mL </p>
<p>(2Â½ tsp)</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">37.5 mL</p></td>
<td class="Botrule" align="center"><p class="First">1500 mg</p></td>
</tr>
</tbody>
</table>
<table width="100%">
<col width="13%">
<col width="14%">
<col width="14%">
<col width="30%">
<col width="29%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="5"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">OTITIS MEDIA</span>: (1 Day Regimen)</span></p></td></tr>
<tr><td class="Botrule" align="center" colspan="5"><p class="First"><span class="Bold">Dosing Calculated on 30 mg/kg as a single dose.</span></p></td></tr>
<tr>
<td class="Botrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">Weight</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">200 mg/5 mL</span></p></td>
<td class="Botrule Rrule" rowspan="2"><p class="First"><span class="Bold">Total mL per Treatment Course</span></p></td>
<td class="Botrule" rowspan="2"><p class="First"><span class="Bold">Total mg per Treatment Course</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Kg</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Lbs.</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Day 1</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">3.75 mL</p>
<p>(Â¾ tsp)</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">3.75 mL</p></td>
<td class="Botrule" align="center"><p class="First">150 mg</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">10</p></td>
<td class="Botrule Rrule" align="center"><p class="First">22</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">7.5 mL</p>
<p>(1Â½ tsp)</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">7.5 mL</p></td>
<td class="Botrule" align="center"><p class="First">300 mg</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">20</p></td>
<td class="Botrule Rrule" align="center"><p class="First">44</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">15 mL</p>
<p>(3 tsp)</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">15 mL</p></td>
<td class="Botrule" align="center"><p class="First">600 mg</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">30</p></td>
<td class="Botrule Rrule" align="center"><p class="First">66</p></td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">22.5 mL</p>
<p>(4Â½ tsp)</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">22.5 mL</p></td>
<td class="Botrule" align="center"><p class="First">900 mg</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">40</p></td>
<td class="Botrule Rrule" align="center"><p class="First">88</p></td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">30 mL</p>
<p>(6 tsp)</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">30 mL</p></td>
<td class="Botrule" align="center"><p class="First">1200 mg</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="center"><p class="First">50 and above</p></td>
<td class="Botrule Rrule" align="center"><p class="First">110 and above</p></td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">37.5 mL</p>
<p>(7Â½ tsp)</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">37.5 mL</p></td>
<td class="Botrule" align="center"><p class="First">1500 mg</p></td>
</tr>
</tbody>
</table>
<p>The safety of re-dosing azithromycin in pediatric patients who vomit after receiving 30 mg/kg as a single dose has not been established. In clinical studies involving 487 patients with acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> given a single 30 mg/kg dose of azithromycin, eight patients who <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomited</span> within 30 minutes of dosing were re-dosed at the same total dose.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span>: </span>The recommended dose of azithromycin for oral suspension for children with <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> is 12 mg/kg once daily for 5 days. (See chart below.)</p>
<a name="_Refid_78ba5438-019c-4004-9ed6-f5be8d0e0"></a><table width="100%">
<caption><span>PEDIATRIC DOSAGE GUIDELINES FOR <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">PHARYNGITIS</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">TONSILLITIS</span> (Age 2 years and above, see PRECAUTIONS, <a href="#i4i_pediatric_use_id_185a14d9-8f7f-47e0-adf0-f361468c8b03">Pediatric Use</a>.) Based on Body Weight</span></caption>
<col width="5%">
<col width="7%">
<col width="15%">
<col width="34%">
<col width="20%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="5"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">PHARYNGITIS</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">TONSILLITIS</span>: (5 Day Regimen)</span></p></td></tr>
<tr><td class="Botrule" align="center" colspan="5"><p class="First"><span class="Bold">Dosing Calculated on 12 mg/kg/day for 5 days.</span></p></td></tr>
<tr>
<td class="Botrule Rrule" align="center" colspan="2"><p class="First"><span class="Bold">Weight</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">200 mg/5 mL</span></p></td>
<td class="Botrule Rrule" rowspan="2"><p class="First"><span class="Bold">Total mL per Treatment Course</span></p></td>
<td class="Botrule" rowspan="2">
<p class="First"><span class="Bold">Total mg per</span></p>
<p><span class="Bold">Treatment Course</span></p>
</td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Kg</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Lbs.</span></p></td>
<td class="Botrule"><p class="First"><span class="Bold">Day 1 to 5</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">8</p></td>
<td class="Botrule Rrule"><p class="First">18</p></td>
<td class="Botrule Rrule">
<p class="First">2.5 mL</p>
<p>(Â½ tsp)</p>
</td>
<td class="Botrule Rrule"><p class="First">12.5 mL</p></td>
<td class="Botrule"><p class="First">500 mg</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">17</p></td>
<td class="Botrule Rrule"><p class="First">37</p></td>
<td class="Botrule Rrule">
<p class="First">5 mL</p>
<p>(1 tsp)</p>
</td>
<td class="Botrule Rrule"><p class="First">25 mL</p></td>
<td class="Botrule"><p class="First">1000 mg</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">25</p></td>
<td class="Botrule Rrule"><p class="First">55</p></td>
<td class="Botrule Rrule">
<p class="First">7.5 mL</p>
<p>(1Â½ tsp)</p>
</td>
<td class="Botrule Rrule"><p class="First">37.5 mL</p></td>
<td class="Botrule"><p class="First">1500 mg</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">33</p></td>
<td class="Botrule Rrule"><p class="First">73</p></td>
<td class="Botrule Rrule">
<p class="First">10 mL</p>
<p>(2 tsp)</p>
</td>
<td class="Botrule Rrule"><p class="First">50 mL</p></td>
<td class="Botrule"><p class="First">2000 mg</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First">40</p></td>
<td class="Botrule Rrule"><p class="First">88</p></td>
<td class="Botrule Rrule">
<p class="First">12.5 mL</p>
<p>(2Â½ tsp)</p>
</td>
<td class="Botrule Rrule"><p class="First">62.5 mL</p></td>
<td class="Botrule"><p class="First">2500 mg</p></td>
</tr>
</tbody>
</table>
<p>Constituting instructions for azithromycin for oral suspension, 300, 600, 900, 1200 mg bottles. The table below indicates the volume of water to be used for constitution:</p>
<table width="100%">
<col width="17%">
<col width="45%">
<col width="38%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">
<p class="First">Amount of </p>
<p><span class="Underline">water to be added</span></p>
</td>
<td class="Botrule Rrule Toprule"><p class="First">Total volume after constitution <span class="Underline">(azithromycin content)</span></p></td>
<td class="Botrule Rrule Toprule"><p class="First">Azithromycin concentration <span class="Underline">after constitution</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">9 mL (300 mg)</p></td>
<td class="Botrule Rrule"><p class="First">15 mL (300 mg)</p></td>
<td class="Botrule Rrule"><p class="First">100 mg/5 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">9 mL (600 mg)</p></td>
<td class="Botrule Rrule"><p class="First">15 mL (600 mg)</p></td>
<td class="Botrule Rrule"><p class="First">200 mg/5 mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">12 mL (900 mg)</p></td>
<td class="Botrule Rrule"><p class="First">22.5 mL (900 mg)</p></td>
<td class="Botrule Rrule"><p class="First">200 mg/5 mL</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">15 mL (1200 mg)</p></td>
<td class="Botrule Rrule"><p class="First">30 mL (1200 mg)</p></td>
<td class="Botrule Rrule"><p class="First">200 mg/5 mL</p></td>
</tr>
</tbody>
</table>
<p>Shake well before each use. Oversized bottle provides shake space. Keep tightly closed.</p>
<p>After mixing, store suspension at 5Â° to 25Â°C (41Â° to 77Â°F) and use within 10 days. Discard after full dosing is completed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_601027df-a137-439d-9140-31b4ee7964ec"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Azithromycin for oral suspension USP after constitution contains a flavored pink suspension. Azithromycin for oral suspension USP is supplied to provide 100 mg/5 mL or 200 mg/5 mL suspension in bottles as follows:</p>
<p>100mg/5 mL 15cc bottle - 68788-9958-1</p>
<p>200mg/5 mL 30cc bottle - 68788-9959-3</p>
<div class="Warning">
<a name="id_ddbd25a3-2041-4fba-ae9d-8a255e68e13a"></a><a name="section-10.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Underline">Azithromycin contents per bottle</span></p>
<p>300 mg</p>
<p>600 mg</p>
<p>900 mg</p>
<p>1200 mg</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e19f5ada-25d7-4a7d-a013-63f89df12284"></a><a name="section-10.1"></a><p></p>
<p class="First">Â </p>
<p>See<span class="Bold"><a href="#i4i_dosage_admin_id_5f9a39bc-e310-40e9-87ca-c4002c87c14d">DOSAGE AND ADMINISTRATION</a></span>for constitution instructions with each bottle type.</p>
<p>Storage: Store dry powder at 20Â° to 25Â°C (68Â° to 77Â°F)[See USP Controlled Room Temperature]. Store constituted suspension between 5Â° to 25Â°C (41Â° to 77Â°F) and discard when full dosing is completed. </p>
<p>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_4b74d96a-0f10-4ff9-9535-f64f5e3961ad"></a><a name="section-11"></a><p></p>
<h1>CLINICAL STUDIES </h1>
<p class="First">See<span class="Bold"><a href="#i4i_indications_id_b7d8c67f-6ac6-49d6-ac4f-d30514926001">INDICATIONS AND USAGE</a></span>and<span class="Bold"><a href="#i4i_pediatric_use_id_185a14d9-8f7f-47e0-adf0-f361468c8b03">Pediatric Use</a>.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7967a64e-4354-4a79-b282-0959f9cf0651"></a><a name="section-11.1"></a><p></p>
<h2>Pediatric Patients</h2>
<p class="First">From the perspective of evaluating pediatric clinical trials, Days 11 to 14 were considered on-therapy evaluations because of the extended half-life of azithromycin. Day 11 to 14 data are provided for clinical guidance. Day 24 to 32 evaluations were considered the primary test of cure endpoint.</p>
<p><span class="Bold">Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span></span></p>
<p><span class="Bold">Safety and efficacy using azithromycin 30 mg/kg given over 5 days</span></p>
<p>Protocol 1</p>
<p>In a double-blind, controlled clinical study of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> performed in the United States, azithromycin (10 mg/kg on Day 1 followed by 5 mg/kg on Days 2 to 5) was compared to amoxicillin/clavulanate potassium (4:1). For the 553 patients who were evaluated for clinical efficacy, the clinical success rate (i.e., cure plus improvement) at the Day 11 visit was 88% for azithromycin and 88% for the control agent. For the 521 patients who were evaluated at the Day 30 visit, the clinical success rate was 73% for azithromycin and 71% for the control agent.</p>
<p>In the safety analysis of the above study, the incidence of treatment-related adverse events, primarily gastrointestinal, in all patients treated was 9% with azithromycin and 31% with the control agent. The most common side effects were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (4% azithromycin vs. 20% control), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (2% azithromycin vs. 7% control), and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (2% azithromycin vs. 5% control).</p>
<p>Protocol 2</p>
<p>In a non-comparative clinical and microbiologic trial performed in the United States, where significant rates of beta-lactamase producing organisms (35%) were found, 131 patients were evaluable for clinical efficacy. The combined clinical success rate (i.e., cure and improvement) at the Day 11 visit was 84% for azithromycin. For the 122 patients who were evaluated at the Day 30 visit, the clinical success rate was 70% for azithromycin.</p>
<p>Microbiologic determinations were made at the pre-treatment visit. Microbiology was not reassessed at later visits. The following presumptive bacterial/clinical cure outcomes (i.e., clinical success) were obtained from the evaluable group:</p>
<p>Presumed Bacteriologic Eradication</p>
<table width="100%">
<col width="16%">
<col width="16%">
<col width="15%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule">
<p class="First">Day 11 </p>
<p>Azithromycin</p>
</td>
<td class="Botrule Rrule Toprule">
<p class="First">Day 30</p>
<p>Azithromycin</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">S. pneumoniae</span></p></td>
<td class="Botrule Rrule"><p class="First">61/74 (82%)</p></td>
<td class="Botrule Rrule"><p class="First">40/56 (71%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">H. influenzae</span></p></td>
<td class="Botrule Rrule"><p class="First">43/54 (80%)</p></td>
<td class="Botrule Rrule"><p class="First">30/47 (64%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">M. catarrhalis</span></p></td>
<td class="Botrule Rrule"><p class="First">28/35 (80%)</p></td>
<td class="Botrule Rrule"><p class="First">19/26 (73%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">S. pyogenes</span></p></td>
<td class="Botrule Rrule"><p class="First">11/11 (100%)</p></td>
<td class="Botrule Rrule"><p class="First">7/7</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Overall</p></td>
<td class="Botrule Rrule"><p class="First">177/217 (82%)</p></td>
<td class="Botrule Rrule"><p class="First">97/137 (73%)</p></td>
</tr>
</tbody>
</table>
<p>In the safety analysis of this study, the incidence of treatment-related adverse events, primarily gastrointestinal, in all patients treated was 9%. The most common side effect was <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (4%).</p>
<p>Protocol 3</p>
<p>In another controlled comparative clinical and microbiologic study of <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> performed in the United States, azithromycin was compared to amoxicillin/clavulanate potassium (4:1). This study utilized two of the same investigators as Protocol 2 (above), and these two investigators enrolled 90% of the patients in Protocol 3. For this reason, Protocol 3 was not considered to be an independent study. Significant rates of beta-lactamase producing organisms (20%) were found. Ninety-two (92) patients were evaluable for clinical and microbiologic efficacy. The combined clinical success rate (i.e., cure and improvement) of those patients with a baseline pathogen at the Day 11 visit was 88% for azithromycin vs. 100% for control; at the Day 30 visit, the clinical success rate was 82% for azithromycin vs. 80% for control.</p>
<p>Microbiologic determinations were made at the pre-treatment visit. Microbiology was not reassessed at later visits. At the Day 11 and Day 30 visits, the following presumptive bacterial/clinical cure outcomes (i.e., clinical success) were obtained from the evaluable group:</p>
<p>Presumed Bacteriologic Eradication</p>
<table width="100%">
<col width="16%">
<col width="15%">
<col width="15%">
<col width="15%">
<col width="14%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"><p class="First">Day 11</p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"><p class="First">Day 30</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"><p class="First">Azithromycin</p></td>
<td class="Botrule Rrule"><p class="First">Control</p></td>
<td class="Botrule Rrule"><p class="First">Azithromycin</p></td>
<td class="Botrule Rrule"><p class="First">Control</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">S. pneumoniae</span></p></td>
<td class="Botrule Rrule"><p class="First">25/29 (86%)</p></td>
<td class="Botrule Rrule"><p class="First">26/26 (100%)</p></td>
<td class="Botrule Rrule"><p class="First">22/28 (79%)</p></td>
<td class="Botrule Rrule"><p class="First">18/22 (82%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">H. influenzae</span></p></td>
<td class="Botrule Rrule"><p class="First">9/11 (82%)</p></td>
<td class="Botrule Rrule"><p class="First">9/9</p></td>
<td class="Botrule Rrule"><p class="First">8/10 (80%)</p></td>
<td class="Botrule Rrule"><p class="First">6/8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">M. catarrhalis</span></p></td>
<td class="Botrule Rrule"><p class="First">7/7</p></td>
<td class="Botrule Rrule"><p class="First">5/5</p></td>
<td class="Botrule Rrule"><p class="First">5/5</p></td>
<td class="Botrule Rrule"><p class="First">2/3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">S. pyogenes</span></p></td>
<td class="Botrule Rrule"><p class="First">2/2</p></td>
<td class="Botrule Rrule"><p class="First">5/5</p></td>
<td class="Botrule Rrule"><p class="First">2/2</p></td>
<td class="Botrule Rrule"><p class="First">4/4</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Overall</p></td>
<td class="Botrule Rrule"><p class="First">43/49 (88%)</p></td>
<td class="Botrule Rrule"><p class="First">45/45 (100%)</p></td>
<td class="Botrule Rrule"><p class="First">37/45 (82%)</p></td>
<td class="Botrule Rrule"><p class="First">30/37 (81%)</p></td>
</tr>
</tbody>
</table>
<p>In the safety analysis of the above study, the incidence of treatment-related adverse events, primarily gastrointestinal, in all patients treated was 4% with azithromycin and 31% with the control agent. The most common side effect was <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (2% azithromycin vs. 29% control).</p>
<p><span class="Bold">Safety and efficacy using azithromycin 30 mg/kg given over 3 days</span></p>
<p>Protocol 4</p>
<p>In a double-blind, controlled, randomized clinical study of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> in pediatric patients from 6 months to 12 years of age, azithromycin (10 mg/kg per day for 3 days) was compared to amoxicillin/clavulanate potassium (7:1) in divided doses q12h for 10 days. Each patient received active drug and placebo matched for the comparator.</p>
<p>For the 366 patients who were evaluated for clinical efficacy at the Day 12 visit, the clinical success rate (i.e., cure plus improvement) was 83% for azithromycin and 88% for the control agent. For the 362 patients who were evaluated at the Day 24 to 28 visit, the clinical success rate was 74% for azithromycin and 69% for the control agent.</p>
<p>In the safety analysis of the above study, the incidence of treatment-related adverse events, primarily gastrointestinal, in all patients treated was 10.6% with azithromycin and 20% with the control agent. The most common side effects were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (5.9% azithromycin vs. 14.6% control), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (2.1% azithromycin vs. 1.1% control), and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (0% azithromycin vs. 4.3% control).</p>
<p><span class="Bold">Safety and efficacy using azithromycin 30 mg/kg given as a single dose</span></p>
<p>Protocol 5</p>
<p>A double-blind, controlled, randomized trial was performed at nine clinical centers. Pediatric patients from 6 months to 12 years of age were randomized 1:1 to treatment with either azithromycin (given at 30 mg/kg as a single dose on Day 1) or amoxicillin/clavulanate potassium (7:1), divided q12h for 10 days. Each child received active drug, and placebo matched for the comparator.</p>
<p>Clinical response (Cure, Improvement, Failure) was evaluated at End of Therapy (Day 12 to 16) and Test of Cure (Day 28 to 32). Safety was evaluated throughout the trial for all treated subjects. For the 321 subjects who were evaluated at End of Treatment, the clinical success rate (cure plus improvement) was 87% for azithromycin, and 88% for the comparator. For the 305 subjects who were evaluated at Test of Cure, the clinical success rate was 75% for both azithromycin and the comparator.</p>
<p>In the safety analysis, the incidence of treatment-related adverse events, primarily gastrointestinal, was 16.8% with azithromycin, and 22.5% with the comparator. The most common side effects were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (6.4% with azithromycin vs. 12.7% with the comparator), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (4% with each agent), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (1.7% with azithromycin vs. 5.2% with the comparator) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (1.7% with azithromycin vs. 1.2% with the comparator).</p>
<p>Protocol 6</p>
<p>In a non-comparative clinical and microbiological trial, 248 patients from 6 months to 12 years of age with documented acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> were dosed with a single oral dose of azithromycin (30 mg/kg on Day 1). </p>
<p>For the 240 patients who were evaluable for clinical modified Intent-to-Treat (MITT) analysis, the clinical success rate (i.e., cure plus improvement) at Day 10 was 89% and for the 242 patients evaluable at Day 24 to 28, the clinical success rate (cure) was 85%.</p>
<p>Presumed Bacteriologic Eradication</p>
<table width="100%">
<col width="16%">
<col width="16%">
<col width="16%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule"><p class="First">Day 10</p></td>
<td class="Botrule Rrule Toprule"><p class="First">Day 24 to 28</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">S. pneumoniae</span></p></td>
<td class="Botrule Rrule"><p class="First">70/76 (92%)</p></td>
<td class="Botrule Rrule"><p class="First">67/76 (88%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">H. influenzae</span></p></td>
<td class="Botrule Rrule"><p class="First">30/42 (71%)</p></td>
<td class="Botrule Rrule"><p class="First">28/44 (64%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">M. catarrhalis</span></p></td>
<td class="Botrule Rrule"><p class="First">10/10 (100%)</p></td>
<td class="Botrule Rrule"><p class="First">10/10 (100%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Overall</p></td>
<td class="Botrule Rrule"><p class="First">110/128 (86%)</p></td>
<td class="Botrule Rrule"><p class="First">105/130 (81%)</p></td>
</tr>
</tbody>
</table>
<p>In the safety analysis of this study, the incidence of treatment-related adverse events, primarily gastrointestinal, in all the subjects treated was 12.1%. The most common side effects were <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (5.6%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (3.2%), and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (1.6%).</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span></span></p>
<p>In three double-blind controlled studies, conducted in the United States, azithromycin (12 mg/kg once a day for 5 days) was compared to penicillin V (250 mg three times a day for 10 days) in the treatment of <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> due to documented Group A Î²-hemolytic streptococci (GABHS or <span class="Italics">S. pyogenes</span>). Azithromycin was clinically and microbiologically statistically superior to penicillin at Day 14 and Day 30 with the following clinical success (i.e., cure and improvement) and bacteriologic efficacy rates (for the combined evaluable patient with documented GABHS):</p>
<p>                               Three U.S. <span class="product-label-link" type="condition" conceptid="28060" conceptname="Streptococcal sore throat">Streptococcal Pharyngitis</span> Studies</p>
<p>                                            Azithromycin vs. Penicillin V</p>
<p>                                                 EFFICACY RESULTS</p>
<table width="100%">
<col width="42%">
<col width="16%">
<col width="16%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule"><p class="First">Day 14</p></td>
<td class="Botrule Rrule Toprule"><p class="First">Day 30</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Bacteriologic Eradication:</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> Azithromycin</p></td>
<td class="Botrule Rrule"><p class="First">323/340 (95%)</p></td>
<td class="Botrule Rrule"><p class="First">255/330 (77%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> Penicillin V</p></td>
<td class="Botrule Rrule"><p class="First">242/332 (73%)</p></td>
<td class="Botrule Rrule"><p class="First">206/325 (63%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Clinical Success (Cure plus improvement):</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"> Azithromycin</p></td>
<td class="Botrule Rrule"><p class="First">336/343 (98%)</p></td>
<td class="Botrule Rrule"><p class="First">310/330 (94%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"> Penicillin V</p></td>
<td class="Botrule Rrule"><p class="First">284/338 (84%)</p></td>
<td class="Botrule Rrule"><p class="First">241/325 (74%)</p></td>
</tr>
</tbody>
</table>
<p>Approximately 1% of azithromycin-susceptible <span class="Italics">S. pyogenes </span>isolates were resistant to azithromycin following therapy.</p>
<p>The incidence of treatment-related adverse events, primarily gastrointestinal, in all patients treated was 18% on azithromycin and 13% on penicillin. The most common side effects were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (6% azithromycin vs. 2% penicillin), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (6% azithromycin vs. 4% penicillin), and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (3% azithromycin vs. 1% penicillin).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4eba0cf1-334f-45fd-b156-f8dc778a35fc"></a><a name="section-11.2"></a><p></p>
<h2>Adult Patients</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3a4581cf-8c19-4a6a-b36a-e032034ae578"></a><a name="section-11.2.1"></a><p></p>
<h3><span class="Bold">Acute Bacterial Exacerbations of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">Chronic Obstructive Pulmonary Disease</span></span></h3>
<p class="First">In a randomized, double-blind controlled clinical trial of <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">acute exacerbation of chronic bronchitis</span> (AECB), azithromycin (500 mg once daily for 3 days) was compared with clarithromycin (500 mg twice daily for 10 days). The primary endpoint of this trial was the clinical cure rate at Day 21 to 24. For the 304 patients analyzed in the modified intent to treat analysis at the Day 21 to 24 visit, the clinical cure rate for 3 days of azithromycin was 85% (125/147) compared to 82% (129/157) for 10 days of clarithromycin.</p>
<p>The following outcomes were the clinical cure rates at the Day 21 to 24 visit for the bacteriologically evaluable patients by pathogen:</p>
<table width="100%">
<col width="16%">
<col width="16%">
<col width="18%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold"> Pathogen</span></p></td>
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold">Azithromycin</span></p></td>
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold">Clarithromycin</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">(3 Days)</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold">(10 Days)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">S. pneumoniae</span></p></td>
<td class="Botrule Rrule"><p class="First">29/32 (91%)</p></td>
<td class="Botrule Rrule"><p class="First">21/27 (78%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">H. influenzae</span></p></td>
<td class="Botrule Rrule"><p class="First">12/14 (86%)</p></td>
<td class="Botrule Rrule"><p class="First">14/16 (88%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">M. catarrhalis</span></p></td>
<td class="Botrule Rrule"><p class="First">11/12 (92%)</p></td>
<td class="Botrule Rrule"><p class="First">12/15 (80%)</p></td>
</tr>
</tbody>
</table>
<p>In the safety analysis of this study, the incidence of treatment-related adverse events, primarily gastrointestinal, were comparable between treatment arms (25% with azithromycin and 29% with clarithromycin). The most common side effects were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> with comparable incidence rates for each symptom of 5 to 9% between the two treatment arms (see <span class="Bold"><a href="#i4i_adverse_effects_id_7511c562-44a3-46e1-8b4c-b8c53d4f62d3">ADVERSE REACTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e4f4dd57-ebd2-41c8-bbaf-3566c366a5a0"></a><a name="section-11.2.2"></a><p></p>
<h3><span class="Bold">Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></span></h3>
<p class="First">In a randomized, double-blind, double-dummy controlled clinical trial of acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, azithromycin (500 mg once daily for 3 days) was compared with amoxicillin/clavulanate (500/125 mg tid for 10 days). Clinical response assessments were made at Day 10 and Day 28. The primary endpoint of this trial was prospectively defined as the clinical cure rate at Day 28. For the 594 patients analyzed in the modified intent to treat analysis at the Day 10 visit, the clinical cure rate for 3 days of azithromycin was 88% (268/303) compared to 85% (248/291) for 10 days of amoxicillin/clavulanate. For the 586 patients analyzed in the modified intent to treat analysis at the Day 28 visit, the clinical cure rate for 3 days of azithromycin was 71.5% (213/298) compared to 71.5% (206/288), with a 97.5% confidence interval of -8.4 to 8.3, for 10 days of amoxicillin/clavulanate. </p>
<p>In the safety analysis of this study, the overall incidence of treatment-related adverse events, primarily gastrointestinal, was lower in the azithromycin treatment arm (31%) than in the amoxicillin/clavulanate arm (51%). The most common side effects were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (17% in the azithromycin arm vs. 32% in the amoxicillin/clavulanate arm), and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (7% in the azithromycin arm vs. 12% in the amoxicillin/clavulanate arm) (see <span class="Bold"><a href="#i4i_adverse_effects_id_7511c562-44a3-46e1-8b4c-b8c53d4f62d3">ADVERSE REACTIONS</a></span>).</p>
<p>In an open label, noncomparative study requiring baseline transantral sinus punctures the following outcomes were the clinical success rates at the Day 7 and Day 28 visits for the modified intent to treat patients administered 500 mg of azithromycin once daily for 3 days with the following pathogens:</p>
<table width="100%">
<col width="16%">
<col width="15%">
<col width="15%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><br><span class="Bold">Pathogen</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Azithromycin</span><br><span class="Bold">(500 mg per day for 3 Days)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold"><span class="Italics">Day 7</span></span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="Bold"><span class="Italics">Day 28</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">S. pneumoniae</span></p></td>
<td class="Botrule Rrule"><p class="First">23/26 (88%)</p></td>
<td class="Botrule Rrule"><p class="First">21/25 (84%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">H. influenzae</span></p></td>
<td class="Botrule Rrule"><p class="First">28/32 (87%)</p></td>
<td class="Botrule Rrule"><p class="First">24/32 (75%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">M. catarrhalis</span></p></td>
<td class="Botrule Rrule"><p class="First">14/15 (93%)</p></td>
<td class="Botrule Rrule"><p class="First">13/15 (87%)</p></td>
</tr>
</tbody>
</table>
<p>The overall incidence of treatment-related adverse events in the noncomparative study was 21% in modified intent to treat patients treated with azithromycin at 500 mg once daily for 3 days with the most common side effects being <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (9%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (4%) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3%) (see <span class="Bold"><a href="#i4i_adverse_effects_id_7511c562-44a3-46e1-8b4c-b8c53d4f62d3">ADVERSE REACTIONS</a></span>).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_46c52494-6d09-44a9-8788-1bcdcd10c642"></a><a name="section-12"></a><p></p>
<h1>ANIMAL TOXICOLOGY</h1>
<p class="First">Phospholipidosis (intracellular phospholipid accumulation) has been observed in some tissues of mice, rats, and dogs given multiple doses of azithromycin. It has been demonstrated in numerous organ systems (e.g., eye, dorsal root ganglia, liver, gallbladder, kidney, spleen, and pancreas) in dogs treated with azithromycin at doses which, expressed on the basis of mg/ m<span class="Sup">2</span>, are approximately equal to the recommended adult human dose, and in rats treated at doses approximately one-sixth of the recommended adult human dose. This effect has been shown to be reversible after cessation of azithromycin treatment. Phospholipidosis has been observed to a similar extent in the tissues of neonatal rats and dogs given daily doses of azithromycin ranging from 10 days to 30 days. Based on the pharmacokinetic data, phospholipidosis has been seen in the rat (30 mg/kg dose) at observed C<span class="Sub">max</span> value of 1.3 mcg/mL (six times greater than the observed C<span class="Sub">max</span> of 0.216 mcg/mL at the pediatric dose of 10 mg/kg). Similarly, it has been shown in the dog (10 mg/kg dose) at observed C<span class="Sub">max</span> value of 1.5 mcg/mL (seven times greater than the observed same C<span class="Sub">max</span> and drug dose in the studied pediatric population). On a mg/m<span class="Sup">2</span> basis, 30 mg/kg dose in the neonatal rat (135 mg/m<span class="Sup">2</span>) and 10 mg/kg dose in the neonatal dog (79 mg/m<span class="Sup">2</span>) are approximately 0.5 and 0.3 times, respectively, the recommended dose in the pediatric patients with an average body weight of 25 kg. Phospholipidosis, similar to that seen in the adult animals, is reversible after cessation of azithromycin treatment. The significance of these findings for animals and for humans is unknown.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_6d53d687-99f8-466b-a619-1d72085d8c3a"></a><a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard <span class="Italics">- </span>Ninth Edition<span class="Italics">. </span>CLSI document M07-A9. CLSI 950 West Valley Rd, Suite 250, Wayne, PA 19087, 2012.</dd>
<dt>2.</dt>
<dd>CLSI, Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. CLSI document M100-S22<span class="Bold">. </span>CLSI, Wayne, PA 19087, 2012. </dd>
<dt>3.</dt>
<dd>CLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard - Eleventh Edition. CLSI document M02-A11. CLSI, Wayne, PA 19087, 2012.</dd>
</dl>
<p class="First">Manufactured In Croatia By:</p>
<p><span class="Bold">PLIVA HRVATSKA d.o.o.</span><br>Zagreb, Croatia<br></p>
<p>Manufactured For:</p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA</span><br>Sellersville, PA 18960</p>
<p>Rev. E 2/2013</p>
<p><span class="Bold">Relabeled by Preferred Pharmaceuticals, Inc.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_66ad5e6a-a275-449a-aaf9-50b4dcce544f"></a><a name="section-14"></a><p></p>
<h1>PATIENT SUMMARY OF INFORMATION ABOUT </h1>
<p class="First"><span class="Bold">Azithromycin For Oral Suspension USP </span></p>
<p>Cherry-flavored suspension </p>
<p><span class="Bold">Rx Only </span></p>
<p><span class="Bold">This summary contains important information about azithromycin. </span>It is not meant to take the place of your childâ€™s doctorâ€™s instructions. Read this information carefully before you give azithromycin to your child. Ask your childâ€™s doctor, nurse or pharmacist if you do not understand any of this information or if you want to know more about azithromycin. </p>
<p><span class="Bold">â€¢ What Is Azithromycin? </span></p>
<p>Azithromycin is an antibiotic medicine that is taken only once a day to treat the following types of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in children: <span class="product-label-link" type="condition" conceptid="4044878" conceptname="Infection of ear">ear infections</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, and <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">throat infections</span>. </p>
<p><span class="Bold">â€¢ Can Antibiotics Cure A <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">Cold</span> Or Flu? </span></p>
<p>No. Antibiotics work only on <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by bacteria. They do not kill viruses. No antibiotic, including azithromycin, can treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> such as the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span> and the flu. </p>
<p><span class="Bold">â€¢ What To Tell Your Childâ€™s Doctor Before You Start Azithromycin </span></p>
<p>Only your childâ€™s doctor can decide if azithromycin is right for your child. Before you start azithromycin, be sure to tell the doctor if your child: </p>
<dl>
<dt>â€¢</dt>
<dd>is being given any prescription medicines, including those for <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> </dd>
<dt>â€¢</dt>
<dd>is being given any over-the-counter medicines you can buy without a prescription, including natural/herbal remedies </dd>
<dt>â€¢</dt>
<dd>has ever had any liver or kidney problems </dd>
<dt>â€¢</dt>
<dd>has any other medical problems </dd>
<dt>â€¢</dt>
<dd>is allergic to any medicines </dd>
<dt>â€¢</dt>
<dd>is allergic to certain antibiotics such as erythromycin </dd>
<dt>â€¢</dt>
<dd>is allergic to azithromycin or any of the ingredients of azithromycin suspension. Your doctor or pharmacist can give you a list of these ingredients. </dd>
</dl>
<p><span class="Bold">â€¢ Azithromycin And Other Medicines </span></p>
<p>Some medicines can affect how well azithromycin works. Check with your childâ€™s doctor before giving your child any new medicines. </p>
<p><span class="Bold">â€¢ What Is The Right Amount Of Azithromycin To Give To My Child? </span></p>
<p>Azithromycin gets deep into infected tissue where it is released slowly over time so the medicine keeps fighting bacteria for many days after the last dose is taken. This is why azithromycin may be taken for as short a time as one day. Your childâ€™s doctor will decide the total amount of azithromycin to give to your child, depending on your childâ€™s weight and on the specific <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> your child has. In addition to deciding the total amount of azithromycin to give to your child, the doctor will tell you to give all the medicine to your child in 1 day or to divide it over 3 days or over 5 days. </p>
<p><span class="Bold">For Ear lnfections</span></p>
<p>For <span class="product-label-link" type="condition" conceptid="4044878" conceptname="Infection of ear">ear infections</span>, your childâ€™s doctor will tell you to give azithromycin to your child in one of the following ways: the total amount as 1 dose on 1 day, or the total amount divided into 1 dose per-day for 3 days or the total amount divided into 1 dose-per-day for 5 days, with a double dose on the first day. Whether given all on 1 day, or divided over 3 days or over 5 days, the total amount of azithromycin you give to your child should be the same.</p>
<p><span class="Bold">For <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> </span></p>
<p>For <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, your childâ€™s doctor will tell you to give azithromycin to your child by dividing the total amount into 1 dose-per-day for 5 days, with a double dose on the first day.</p>
<p><span class="Bold">For Throat lnfections (â€œstrep throatâ€?) </span></p>
<p>For <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">throat infections</span>, your childâ€™s doctor will tell you to give azithromycin to your child by dividing the total amount into 1 dose-per-day for 5 days. When you give azithromycin for 5 days for <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">throat infections</span>, you do not need to give a double dose on the first day (as you would with <span class="product-label-link" type="condition" conceptid="4044878" conceptname="Infection of ear">ear infections</span>).<br>If you have questions about how to give azithromycin to your child, please ask your childâ€™s doctor, nurse or pharmacist. </p>
<p><span class="Bold">â€¢ How And When To Give Azithromycin </span></p>
<p>Azithromycin may be taken with or without food and may be taken at any time of day.<br>Shake the bottle well just before you give a dose.<br>Give azithromycin for the full number of days prescribed by the doctor, even if your child feels better before finishing all the medicine as prescribed.<br>If you forget to give your child a dose, call the doctor.</p>
<p><span class="Bold">â€¢ When Can I Expect My Child To Begin Feeling Better? </span></p>
<p>Although azithromycinâ€™s dosing is short and you may be able to give all the medicine to your child more easily, you should not expect azithromycin to work faster than other antibiotics which are dosed for up to 10 days. <br>Your childâ€™s doctor or nurse can advise you when your child should begin feeling better. </p>
<p><span class="Bold">â€¢ Possible Side Effects </span></p>
<p>Like all medicines, azithromycin may cause side effects in some children that are usually mild to moderate and go away after the medicine is stopped. The most common ones are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, abdominal (â€œtummyâ€?) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. </p>
<p>As with other antibiotics, if your child develops <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> that becomes severe and watery or does not go away, stop taking the medicine and call the doctor or nurse. This could be a sign of a serious medical problem. <br><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> to azithromycin are rare, but these can be very serious if not treated right away by a doctor. If you think your child might be having an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to azithromycin, stop the medicine and call the doctor right away. If you cannot reach the doctor, go to the nearest hospital emergency room. Symptoms of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> may include trouble breathing; <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, mouth and neck; or severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>. <br>Azithromycin may cause other less common side effects besides those listed here. For a list of all the side effects that have been reported, ask the doctor, nurse or pharmacist for the Azithromycin Professional Package Insert.</p>
<p><span class="Bold">â€¢ What Should I Do If My Child Vomits (Spits Up) The 1 Day Treatment of Azithromycin? </span></p>
<p>If your child vomits within 30 minutes after the 1 day treatment for an <span class="product-label-link" type="condition" conceptid="4044878" conceptname="Infection of ear">ear infection</span>, please call your childâ€™s doctor. </p>
<p><span class="Bold">â€¢ What To Do For An <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> </span></p>
<p>In case of accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, call your childâ€™s doctor right away or go to the nearest emergency room. </p>
<p><span class="Bold">â€¢ How To Store Azithromycin </span></p>
<p>Keep azithromycin out of the reach of children. Azithromycin can be stored at room temperature. You do not have to keep it in the refrigerator. Throw away any medicine that is left over after treatment.</p>
<p>Manufactured in Croatia By:Â </p>
<p><span class="Bold">PLIVA HRVATSKA d.o.o.</span><br>Zagreb, Croatia<br></p>
<p>Manufactured For:Â </p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA</span><br>Sellersville, PA 18960</p>
<p>Rev. A 6/2012</p>
<p><span class="Bold">Relabeled by Preferred Pharmaceuticals, Inc.</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_a1d6b2ab-ba89-4755-9d68-109006d4cc52"></a><a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id2823"></a><img alt="Azithromycin Oral Suspension, USP 100mg* per 5mL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=035ce971-cf46-40c0-9b2f-ae52ab4e3468&amp;name=4c093ab3-1599-4dec-8f7b-6d6b7fa233b2-02.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_00ebe5da-252e-4779-bf9f-2fb5f0194286"></a><a name="section-15.1"></a><p></p>
<h2>Azithromycin for Oral Suspension USP 100 mg per 5 mL 300 mg Label Text</h2>
<p class="First"><span class="Bold">AZITHROMYCIN for Oral Suspension USP</span><br><span class="Bold">100 mg* per 5 mL</span><br>300 mg (15 mL when mixed)<br><span class="Bold">*</span>When constituted as directed, each<br>teaspoonful (5 mL) contains azithromycin<br>monohydrate equivalent to 100 mg of<br>azithromycin.<br><span class="Bold">FOR ORAL USE ONLY.</span><br><span class="Bold">Cherry Flavored</span><br><span class="Bold">Rx only</span><br><span class="Bold">300 mg (15 mL when mixed)</span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_622d3148-8eed-4fdb-89b8-7c7194ca7516"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id2870"></a><img alt="Azithromycin Oral Suspension, USP 200mg* per 5mL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=035ce971-cf46-40c0-9b2f-ae52ab4e3468&amp;name=4c093ab3-1599-4dec-8f7b-6d6b7fa233b2-03.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a74f0935-ed32-43bb-a35e-f26ccd684ed7"></a><a name="section-16.1"></a><p></p>
<h2>Azithromycin for Oral Suspension USP 200 mg per 5 mL 600 mg Label Text</h2>
<p class="First"><span class="Bold">AZITHROMYCIN for Oral Suspension USP</span><br><span class="Bold">200 mg* per 5 mL</span><br>600 mg (15 mL when mixed)<br><span class="Bold">*</span>When constituted as directed, each<br>teaspoonful (5 mL) contains azithromycin<br>monohydrate equivalent to 200 mg of<br>azithromycin.<br><span class="Bold">FOR ORAL USE ONLY.</span><br><span class="Bold">Cherry Flavored</span><br><span class="Bold">Rx only</span><br><span class="Bold">600 mg (15 mL when mixed)</span></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AZITHROMYCINÂ 		
					</strong><br><span class="contentTableReg">azithromycin powder, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68788-9958(NDC:0093-2027)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AZITHROMYCIN MONOHYDRATE</strong> (AZITHROMYCIN ANHYDROUS) </td>
<td class="formItem">AZITHROMYCIN ANHYDROUS</td>
<td class="formItem">100Â mg Â inÂ 5Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, TRIBASIC, ANHYDROUS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>XANTHAN GUM</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">Â Â Â Â </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">CHERRY (BANANA VANILLA) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68788-9958-1</td>
<td class="formItem">15 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065246</td>
<td class="formItem">01/10/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AZITHROMYCINÂ 		
					</strong><br><span class="contentTableReg">azithromycin powder, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68788-9959(NDC:0093-2026)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AZITHROMYCIN MONOHYDRATE</strong> (AZITHROMYCIN ANHYDROUS) </td>
<td class="formItem">AZITHROMYCIN ANHYDROUS</td>
<td class="formItem">200Â mg Â inÂ 5Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, TRIBASIC, ANHYDROUS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>XANTHAN GUM</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">Â Â Â Â </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">CHERRY (BANANA VANILLA) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68788-9959-3</td>
<td class="formItem">30 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065246</td>
<td class="formItem">01/10/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Preferred Pharmaceuticals, Inc.
							(791119022)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Preferred Pharmaceuticals, Inc. (791119022)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Preferred Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">791119022</td>
<td class="formItem">RELABEL(68788-9958, 68788-9959)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3f0bbf9d-09d4-44ed-8b62-cfb509855e8c</div>
<div>Set id: 035ce971-cf46-40c0-9b2f-ae52ab4e3468</div>
<div>Version: 3</div>
<div>Effective Time: 20140710</div>
</div>
</div>Â <div class="DistributorName">Preferred Pharmaceuticals, Inc.</div></p>
</body></html>
